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Abstract 
 
White Blood Cell Growth Factor Utilization among Metastatic 
Colorectal Cancer Patients 
 
 
Chinelo Constance Orji, M.S.P.S 
The University of Texas at Austin, 2019 
 
Supervisor:  Carolyn M. Brown 
 
 Despite the widespread success of chemotherapy in treating various forms of 
cancer, its use is limited by certain toxicities like neutropenia. Colony stimulating factors 
(CSF), when used prophylactically, are useful in preventing febrile neutropenia (FN), as 
well as reducing its duration and severity. The American Society of Clinical Oncology 
(ASCO) guidelines recommend CSF for prophylaxis in cancer patients, but also 
recommend chemotherapy dose reduction as a viable alternative. The goal of this research 
was to assess and compare the use of CSF and dose reduction among metastatic colorectal 
cancer patients and factors that influence their use. The study also tested the impact of a 
program initiative on CSF prescription patterns. 
 For this retrospective observational study, data were obtained from the electronic 
health records of metastatic colorectal cancer patients who received care at a multi-center 
oncology practice network in two time periods. The outcomes of interest were CSF use, 
 vii 
chemotherapy dose reduction and all-cause mortality. Logistic regression techniques were 
utilized in exploring the relationships between these outcomes and some variables namely 
age, gender, FN risk, line of therapy, duration of treatment, year of diagnosis and disease . 
In 2016, a site-wide program initiative was introduced in the oncology practice network, 
with an aim of improving appropriate use of CSFs and compliance to guidelines on CSF 
use. The study had a total of 3426 regimens, corresponding to 2968 unique patients. A total 
of 11% of the patients used CSF (N=387). CSF use was significantly lower in the post-
period, compared to the pre-period (p<0.0001). Compliance to guidelines was significantly 
higher in the post-period, compared to the pre-period (p<0.0001). Among subjects who had 
data on dose reduction (N=508), 58.7% received dose reduction distinctively. Factors that 
were significantly associated with CSF include age, FN risk, gender, line of therapy and 
duration of treatment. Factors associated with dose reduction include FN risk and duration 
of treatment, while factors associated with mortality include age, line of therapy, duration 
of treatment and gender. The study found no difference in mortality between CSF users 
and patients who received dose reduction (p=0.2030).  
 Program initiatives have the potential to positively impact prescription patterns. 
Also, there was no benefit of CSF use over dose reduction in terms of mortality. These 
conclusions could help decrease CSF overutilization and result in enhanced clinical 
practice and cost savings, without compromising health outcomes. 
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CHAPTER 1: INTRODUCTION   
This chapter introduces colorectal cancer, colorectal cancer treatment options and 
treatment complications. It also presents colony-stimulating factors (CSFs) and their 
clinical uses. Finally, it explains the objectives of the study and its significance. 
1.1 COLORECTAL CANCER  
Among cancers that affect both males and females, colorectal cancer is the third 
most common cancer and the second leading cause of cancer mortality in the United States. 
The American Cancer Society (ACS) projects that in 2018 there will be 97,220 cases of 
colon cancer and 43,030 cases of rectal cancer with 50,630 combined deaths.1 Colorectal 
cancer was the leading cancer killer in the United States in the late 1940s and early 1950s.2 
However, incidence and mortality rates have declined overtime. This decline is attributed 
to early detection due to increased screening adherence and varying patterns of risk 
factors.3 While overall death rates have been decreasing, incidence has been on the increase 
amongst young adults. For patients 20 to 34 years of age, incidence rates of both colon and 
rectal cancers have been on the rise. Researchers estimate that in 2030, incidence rates for 
colon cancer will grow by 90 percent for people aged 20 to 34 and by 28 percent for patients 
35 to 49 years, whereas there will be a 38 percent decrease for people aged 50 to 74 years 
and a 45 percent decrease for individuals aged 75 and older.4  
Efforts to reduce colorectal cancer incidence have focused on early detection via 
screening. Screening can prevent colorectal cancer by detecting growths at an early and 
treatable stage.3 Generally, it is recommended by medical groups that individuals whose 
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risk is average begin screening at age 50. The United States Preventive Services Task Force 
(USPSTF) strongly propose screening to continue up to age 75; after that, screening should 
be based on individual patient characteristics. Screening for people older than 85 years is 
not recommended.5 Both USPSTF and ACS have several suggested screening test options 
that differ in reliability, potential harm and costs.  
Colorectal cancer imposes a considerable economic burden on society. A 2000 study 
estimated the economic burden of colorectal cancer in the United States to be in the range 
of $5.5 to 6.5 billion a year.6  
1.2 COLORECTAL CANCER TREATMENT 
The treatment of colorectal cancer largely depends on the spread of disease, but in 
general, the 3 standard treatments include surgery, chemotherapy and radiation therapy. 
Surgery involves an operation in which the cancer is removed. Chemotherapy involves the 
use of drugs to alter growth of cancer cells, either by cell destruction or hindering cell 
division. When chemotherapy is given by oral administration or via injection into the body, 
it is called systemic chemotherapy. When chemotherapy is administered in a specific body 
region or target site, it is known as regional chemotherapy. In radiation therapy, X-rays are 
used to kill the cancer cells, to shrink tumors prior to surgery or for symptom relief. 
External radiation therapy beams radiation to the tumor from the exterior, while internal 
radiation therapy means placing a radioactive substance close to or directly on the tumor.7  
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1.3 TREATMENT COMPLICATIONS  
Despite the widespread use and success of chemotherapy in treating various forms 
of cancer,8 it’s use is limited by certain toxicities.9 Colorectal cancer patients, and all cancer 
patients who undergo chemotherapy, are likely to have complications such as 
neutropenia.10 Neutropenia is the leading toxicity of chemotherapy.10 It has been shown to 
be life threatening, and occurs in 10 to 50 percent of treated patients.11 Febrile neutropenia 
(neutropenia with fever) (FN) has been associated with significant morbidity and mortality 
and can lead to dose reductions and delays which could severely impact the effectiveness 
of chemotherapy.12  
 Neutropenia is characterized by a substantial reduction in neutrophils. Neutrophils 
are the most common and important type of white blood cells. They serve as the body’s 
first major defense against infections because they are vital for fighting bacteria. In adult 
patients, neutropenia is defined as 1500 or less neutrophils per microliter of blood, while a 
count of below 500 per microliter of blood is considered severe.13 Although neutropenia is 
often triggered by chemotherapy, other possible causes include Shwachman-Diamond 
syndrome, Fanconi anemia, severe aplastic anemia, leukemia, viral illnesses and bone 
marrow conditions. Some conditions that increase the risk of neutropenia include cancer, 
leukemia, a weak immune system, chemotherapy and radiotherapy.14  
 While neutropenia does not usually present with symptoms, it leads to an increase 
in risk of infection in the body.13 Several tests may be used to assess neutropenia in patients. 
Some of the tests include a complete blood count (CBC) that measures neutrophil counts, 
an antibody blood test that checks for autoimmune neutropenia, bone marrow cell tests, 
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bone marrow trephine biopsy and cytogenetic and molecular testing of cell structures.14 
Mostly, neutropenia is treated using CSFs (colony stimulating factors), including G-CSF 
and GM-CSF. G-CSFs are a synthetic copy of the hormone that leads to growth of 
neutrophils in the bone marrow. Therefore, G-CFSs can increase neutrophil count. GM-
CSF is a naturally produced glycoprotein with a similar function as G-CSF. Prophylactic 
antibiotics may also be administered.13 Sometimes bone marrow transplants can be 
included in treatment when the G-CSFs are not effective or when leukemia is present.14  
1.4 COLONY-STIMULATING FACTORS 
Colony-stimulating factors , also called white blood cell growth factors, are 
medications that stimulate white blood cell production in the body. Clinically, they are 
used for chemotherapy induced marrow damage and neutropenia. CSFs, when used for 
prophylaxis, are useful in preventing neutropenia in response to chemotherapy, by reducing 
its duration and severity.15 CSFs are supportive medications because they do not treat 
cancers; rather they prevent the occurrence of the side effects of cancer treatment, such as 
infections. Pegylated GCSFs are usually administered once per cycle, as injections 24 
hours after chemotherapy. One of the benefits of CSF medication is that it lowers the 
likelihood of hospitalization for febrile neutropenia. However, CSF administration 
involves multiple injections to deliver the medication which could lead to fever and bone 
pain.16 The four distinct types of CSFs include GM-CSF, G-CSF, MCSF and multipotential 
CSF (interleukin3).17 
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 Currently, the American Society of Clinical Oncology (ASCO) recommends 
primary prophylactic use of CSF in cancer patients when the risk of febrile neutropenia is 
equal to or greater than 20 percent and secondary prophylaxis for patients who have 
experienced a complication from previous CSF use. CSF use is not recommended in 
patients who have a low or intermediate risk of febrile neutropenia. However, equally 
effective and safe chemotherapy regimens that do not require CSF support, as well as dose 
reduction or delay are also recommended as reasonable alternatives to CSF 
administration.18 
1.5 THE RESEARCH PROBLEM 
While CSFs have been shown to be useful in neutropenia prevention and 
management among cancer patients, studies suggest that they are being used outside of 
clinical practice recommendations.19 This misuse is characterized by both underutilization 
and overutilization and has been linked to several patient and physician factors.20 Some 
studies have researched on factors associated with CSF use in various populations of cancer 
patients. A population-based observational study in a cohort of lung and colorectal cancer 
patients found risk regimen and comorbidity to be among the associated factors.21 Another 
study indicated that chemotherapy cycle and risk associated with chemotherapy regimen 
are predictors of CSF administration in elderly cancer patients.22 
 The aim of this study was to describe the characteristics of CSF users in a cohort 
of metastatic colorectal cancer patients, to examine the factors associated with CSF 
administration, dose reduction and mortality in the same population and to evaluate the 
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compliance to practice guidelines on use of CSF. This study will help to pinpoint factors 
associated with inappropriate CSF utilization. Targeting these factors could help decrease 
the inappropriate use of CSFs and may result in enhanced clinical practice, cost savings 
and improved outcomes. 
1.6 LIMITATIONS 
According to the American Cancer Society, there are no available accurate 
mortality statistics on colon and rectal cancers separately due to a common problem of 
misclassification. Often, rectal cancer mortality data are misclassified as colon cancer. The 
significant misclassification is likely to be due to the prevalent use of colon cancer when 
referring to both colon and rectal cancers while passing health information and educational 
messages.3  
 Both colon and rectal cancers have the same pathogenesis, risk factors and 
preventive measures. However, their treatment modalities differ.23 While the focus of this 
thesis is specific to colorectal cancer, the epidemiology of colon cancer is inclusive of 
rectal. Colon cancer information found in the literature is presented here as colon cancer, 
while colorectal cancer information is equally presented as colorectal cancer. Both cancers 
are not used interchangeably in this body of work.  
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CHAPTER 2: LITERATURE REVIEW 
This chapter presents a literature review for this study. The first section provides 
detailed information on colorectal cancer, including its epidemiology, predisposing factors, 
signs and symptoms, prevention, diagnosis, treatment and economic burden. The second 
section reviews neutropenia in detail. The next two sections present information on colony-
stimulating factors (CSF) and guidelines for their use in chemotherapy, respectively. The 
final sections discuss the research questions, models and significance of the study. 
2.1 COLORECTAL CANCER  
Colorectal cancer is characterized by abnormal cell growth in the colon or rectum. 
The colon and rectum (colorectum) make up the large intestine, which is located in the 
lower part of the gastro-intestinal system. The colon is the first and larger part of the large 
intestine while the rectum is the smaller end part. Colorectal cancer usually begins with a 
polyp, which is a non-cancerous growth that forms on the inner lining of the colon or 
rectum and grows slowly over time. The most common growth is an adenomatous polyp, 
also called adenoma.23 Metastatic cancer refers to cancer that has spread to other parts of 
the body other than where it started. When colon cancer spreads, it usually spreads to the 
liver though it could also spread to other organs in the body.  
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Figure 2.1: Anatomy of the Large Intestine 
 
Source: Nordqvist C. Colorectal cancer: What you need to know. Medical News Today 2018; 
https://www.medicalnewstoday.com/articles/155598.php. Accessed May 1, 2019.24 
2.1.1 Epidemiology 
Universally, colorectal cancer is the fourth most commonly diagnosed cancer in 
men and third most common in women.23 It is a major cause of morbidity and mortality, 
and accounts for more than 9 percent of all cancer incidence.25 While colorectal cancer 
rates are rising rapidly in low and middle-income countries, rates remain high in developed 
countries.26 Countries with the highest incidence rates include Australia, New Zealand, 
Canada and the United States.25 Researchers estimate that the global burden of colorectal 
cancer will grow by 60 percent to over 2.2 million new cases and 1.1 million deaths by the 
year 2030.26 
 In the United States, colorectal cancer is the third most common malignancy in both 
men and women and the second cancer killer.3 It is estimated that that 97,220 new cases of 
colon cancer and 43,030 cases of rectal cancer will be diagnosed in 2018. Though the 
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prevalence of colon cancer is similar in both genders, men (49,690) and women (47,530), 
a higher number of men (25,920) than women (17,110) will be diagnosed with rectal 
cancer.1 Since the mid-1980s, colorectal cancer incidence has declined by an average of 
1.6 percent per year. This decline has been attributed to a change in the forms of risk factors 
such as reduction in smoking, early detection and removal of precancerous polyps due to 
increased adherence to screening. Likewise, there has been a substantial decrease in 
mortality rates. Colorectal cancer death rates have been decreasing since 1980 in men and 
1947 in women. The declines in mortality from 1975 to 2000 are attributed to improved 
treatment, changing patterns in risk factors and improved screening.27  
 In the United States, colorectal cancer prevalence is highest in African Americans 
and lowest among Asian and Pacific Islanders (APIs). During the time period 2009 to 2013, 
incidence rates in non-Hispanic blacks (NHBs) (49.2 per 100,000) were about 20 percent 
higher than the rates in non-Hispanic whites (NHWs) (40.2 per 100,000) and 50 percent 
higher than the rates in APIs (32.2 per 100,000). The disparities for mortality rates are 
twice that for incidence. During the time period 2010 through 2014, colorectal cancer death 
rates in NHBs (20.5 per 100,000) were 40 percent higher than the rates in NHWs (14.6 per 
100,000) and twice the rates in APIs (10.3 per 100,000). The higher rates in NHBs are 
associated with unduly low socio-economic status.28 According to the United States Census 
Bureau, the poverty rate in 2016 was 22 percent in blacks compared to 8.8 percent in NHWs 
and 10 percent in Asians.29 
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2.1.2 Predisposing Factors 
Generally, the lifetime risk of developing colorectal cancer is about 1 in 22 (4.6%) 
for men and 1 in 24 (4.2%) for women.30 Approximately 5 percent of Americans will 
develop colorectal cancer in their life time.23 Risk of developing colorectal cancer is 
influenced by both modifiable and non-modifiable factors.  
 Some of the modifiable risk factors include physical inactivity, obesity, certain 
diets, certain medications, smoking and heavy alcohol use. Others include personal or 
family history of colorectal cancer.30 A recent study found that combined lifestyle factors 
such as maintaining a healthy body weight, physical activity, limited alcohol and healthy 
diet reduce the risk of colorectal cancer.31 Physical activity is strongly associated with a 
reduced risk of colon cancer. Studies have shown that people who involve in physical 
activity have a reduced risk of developing both proximal and distal tumors compared to the 
least active people.32 Another study found that people who are more physically active 
before and after colorectal cancer diagnosis are more likely to have lower mortality rates.33 
Obesity also increases the risk of colorectal cancer, although a stronger association exists 
in men than in women and for colon more than rectal cancer. Compared to people who 
maintain a healthy body weight, obese men have a 50 percent higher risk of colon cancer, 
whereas obese women have a 20 percent higher risk of colon cancer. Excess body weight 
before diagnosis reduces the chances of survival. Smoking has also been shown to be 
associated with colorectal cancer and lower colorectal cancer specific survival, especially 
for current smokers.  
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 Finally, persons with some medical conditions or history have an increasked risk 
of colorectal cancer. Individuals who have chronic inflammatory bowel disease have 
double the risk of colorectal cancer compared to the general population. People with Type 
2 diabetes have an increased risk as well. Colorectal cancer could be hereditary as up to 30 
percent of colorectal patients have a family history of the disease.30  Non-
modifiable factors that influence risk include age, sex and ethnicity. The risk of developing 
colorectal cancer increases with age. The median age at diagnosis for colon cancer is 68 in 
men and 72 in women. For rectal cancer, it is 63 years in both men and women. Due to 
increased rates of incidence among younger persons and declining rates in older persons, 
the proportion of diagnosed persons younger than 50 has increased over the years with 
many cases occurring in people who are in their 40s. Also, colorectal cancer incidence rates 
are 30 percent higher in men than in women while mortality rates are 40 percent higher. 
Reasons for this disparity are not completely known but could be due to differences in 
exposures to risk factors like cigarette smoking and sex hormones.34 Also, incidence and 
mortality rates are highest in NHBs and lowest in APIs.  
2.1.3 Signs and Symptoms 
Early colorectal cancer presents without symptoms, but overtime as the tumor 
enlarges, bleeding or intestinal obstruction could occur. Sometimes the blood loss leads to 
anemia, causing weakness, shortness of breath and fatigue. Other symptoms that could 
occur include bloody stools, dark stools, change in shape of stool, constipation, decreased 
appetite and unintentional weight loss.  
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2.1.4 Diagnosis and Staging 
Staging refers to the degree of cancer spread at the time of diagnosis and is 
important for determining possible treatments and assessing disease prognosis. The two 
commonly used staging systems are the TNM system and the Surveillance, Epidemiology, 
and End Results (SEER) staging system. While the TNM is commonly used in clinical 
settings, the SEER is used for descriptive and stat analysis of tumor registry data. The 
description of the SEER summary staging includes in situ, local, regional and distant. In in 
situ, cancer is confined to where it started and has not entered the wall of the colon or 
rectum. In local, the cancer has grown into the colon or rectum wall but has not invaded 
nearby tissues. Regional refers to when the cancer spreads into nearby tissues, while distant 
is the spread of the cancer into other body regions such as the liver.30 
 The clinical staging system commonly used is the American Joint Committee on 
Cancer (AJCC) TNM system. The TNM system is based on three variables: primary tumor 
(T), regional nodes (N) and metastasis (M) and is broadly categorized into five stages. The 
earliest stage is called stage O, and then there are stages I, II, III and IV. Stage II is 
subdivided into stage IIA and stage IIB, while stage III is subdivided into stage IIIA, IIIB 
and IIIC. The lower the staging number, the less the degree of cancer spread. And within a 
stage, an earlier letter means a lower stage. Though there are five broad stages, the TNM 
variables are used to further group the stages more specifically. A combination of these 
terms is used to determine the overall stage of a cancer patient.35 
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 In addition, colorectal cancer can be described by grade, which refers to how 
closely cancer cells look like healthy cells when viewed with the microscope. Here the 
cancerous tissue is compared with a healthy tissue. Usually, healthy tissues are made up of 
diverse cell types. If the cancer is like healthy tissue and comprises different cell groups, it 
is called differentiated or low-grade tumor. On the other hand, if it is not similar to the 
healthy tissue, it is called poorly differentiated or high-grade tumor. The lower the tumor 
grade, the better the prognosis. The grades used in practice include GX, and G1 through 
G4, where: 
 GX: The tumor grade cannot be identified; 
 G1: The cells are more like healthy cells (well differentiated); 
 G2: The cells are somewhat like healthy cells (moderately differentiated); 
 G3: The cells look less like healthy cells (poorly differentiated); and 
 G4: The cells barely look like healthy cells (undifferentiated). 
2.1.5 General Cancer Classification 
2.1.5.1 Histologic Classes 
There are two ways cancers can be classified: (1) histologically, which is by the 
type of tissue in which the cancer originates and (2) by primary site, which is the location 
where the cancer first developed. Using the histological classification, cancer can be 
grouped into 6 major categories:  carcinoma, sarcoma, myeloma, leukemia, lymphoma and 
mixed types. 
 14 
Carcinoma: A carcinoma is a malignant neoplasm that arises from the epithelial 
tissues of the skin or a cancer of the internal or external lining in the body. Epithelial tissues 
are present throughout the body. The two major subtypes of carcinomas include 
adenocarcinoma, which develops in an organ and squamous cell carcinoma that originates 
in the squamous epithelium. Carcinomas account for 80 to 90 percent of all cancer cases. 
Sarcoma: Sarcoma refers to cancer that originates in supportive and connective 
tissues such as bones, tendons, cartilage, muscle and fat. It generally occurs in young 
adults. 
Myeloma: Myeloma is cancer that originates in the plasma cells of the bone 
marrow. Some proteins in the blood are produced by plasma cells. 
Leukemia: Leukemias are cancers of the bone marrow. They are also liquid cancers 
or blood cancers. Blood cells are produced in the bone marrow. Leukemias are often 
characterized by overproduction of immature white blood cells which makes the patient 
vulnerable to infection. Leukemias are more common in children.  
Lymphoma: Lymphomas are cancers that develop in the glands and nodes of the 
lymphatic system. The lymphatic system is a network of vessels, nodes and organs that 
purify fluids of the body and produce infection-fighting white blood cells or lymphocytes. 
Unlike leukemias that are liquid cancers, lymphomas are solid cancers. Lymphomas also 
occur in specific organs like breast or brain. The two categories of lymphomas are Hodgkin 
lymphoma and Non-Hodgkin lymphoma.  
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Mixed Types: Some of the mixed types of cancers may be within one category or 
from different categories. Examples include carcinosarcoma and adenosquamous 
carcinoma.36 
2.1.5.2 Solid vs Liquid Tumors 
Solid tumors are abnormal masses of tissue that usually do not contain cysts or 
liquid areas. Solid tumors may be benign (not cancerous) or malignant (cancerous). 
Leukemias (cancer of the blood) generally do not form solid tumors.37 On the other hand, 
liquid tumors consist of neoplastic cells whose precursors are usually mobile.38 
2.1.5.3 Myeloid vs Non-Myeloid Cancers 
Myeloid cancers are leukemias that involve myeloid cells known as myelocytes. 
Non-myeloid cancers are cancers that do not involve myeloid cells (i.e., cancers other than 
myeloid leukemias). Non-myeloid cancers include all types of carcinoma, sarcoma, 
melanoma, lymphomas, lymphocytic leukemias and multiple myelomas.39  
2.1.6 Prevention 
Colorectal cancer screening can prevent cancer through early detection and removal 
of pre-cancerous growths. Screening detects cancer at an early stage when treatment is 
more likely to be successful. Thus, screening reduces cancer death by reducing incidence 
and increasing the chances of patient survival. The USPSTF recommends that adults age 
50 to 75 be screened and screening after age 75 should be made on an individual basis.40 
Also, screening before age 50 can be done for people at increased risk due to certain factors.  
Both USPSTF and ACS have a number of recommended screening test options that differ 
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in reliability, potential harm and costs. The screening guidelines can be found in Figure 2.2 
and Table 2.1 below. 
 
Figure 2.2: USPTSF Guidelines on Colorectal Cancer Screening, 2016  
 
 
A: The USPSTF recommends the service. There is high certainty that the net benefit is substantial. 
C: The USPSTF recommends selectively offering or providing this service to individual patients based on professional judgment and 
patient preferences. There is at least moderate certainty that the net benefit is small. 
 
Source: Final Recommendation Statement: Colorectal Cancer Screening. United States Preventive Services 
Task Force 2016; 
https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/colorectal
-cancer-screening2. Accessed Feb 23, 2018.41 
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Table 2.1: ACS Guidelines on Colorectal Cancer Screening for Average and 
Increased Risk  
 
 
Source: Colorectal Cancer Screening Guidelines Update. US Pharmacist 2012; 
https://www.uspharmacist.com/article/colorectal-cancer-screening-guidelines-update. Accessed Feb 
23, 2018.42 
 
There are several recommended tests for colorectal cancer screening, and each has 
its advantages and disadvantages. There are tests that find both polyps and cancer, and tests 
that find only cancer. Usually, the test a patient utilizes depends on preferences and medical 
condition. 
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2.1.6.1 Tests that Can Find both Colorectal Polyps and Cancer 
i. Flexible Sigmoidoscopy: This involves an examination of the rectum and parts of 
the lower colon (sigmoid colon) to detect, examine and possibly remove 
abnormalities using a sigmoidoscope.43 A sigmoidoscope is a flexible lighted tube 
with a small video camera on the end. The instrument is inserted through the anus 
and air is pumped into the colon for a clearer view. It is minimally invasive and 
usually does not require sedation. The two types of sigmoidoscopy are a flexible 
and rigid sigmoidoscopy. While a flexible sigmoidoscopy uses a flexible 
endoscope, a rigid sigmoidoscopy uses a rigid device. This is, however, not a 
widely used screening test in the United States. It is generally recommended to have 
a sigmoidoscopy every 5 years with or without Guaiac-based fecal occult blood test 
(gFOBT) or every 10 years with a fecal immunochemical test  (FIT).43,44  
 Studies show that flexible sigmoidoscopy is associated with significant 
reduction in colorectal cancer incidence and mortality. People who utilize 
sigmoidoscopy screening after age 50 have a 60 to 70 percent lower risk of death 
due to colorectal cancer than those who do not get the screening.45,46 The test 
identifies both cancers and precursor lesions (including polyps). If an adenoma or 
colorectal cancer is found, a colonoscopy would be required. 
ii. Standard Colonoscopy: In this test, the physician uses a colonoscope to examine 
the entire length of the colon and the rectum. The colonoscope is a thin tube with a 
small video camera on the end and a tool for removing tissue. It is basically a longer 
sigmoidoscope and reaches parts of the colon a sigmoidoscope cannot reach. 
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During a colonoscopy, abnormal growths found in the colon and rectum are 
removed if necessary. Mostly, sedation is required for this test. It is recommended 
to have a colonoscopy every 10 years for people at average risk. Studies have shown 
that colonoscopy reduces mortality due to colorectal cancer.44   
iii. Virtual Colonoscopy: This test is an advanced computed tomography. The virtual 
colonoscopy involves the use of a special x-ray equipment, called a computed 
tomography (CT) scanner to take several pictures of the colon and rectum from 
outside the body. A computer then assembles the pictures into detailed images, 
showing polyps and other abnormalities. This method is less invasive than a 
standard colonoscopy and does not require sedation. However, a colonoscopy is 
still needed to explore or remove any abnormalities found.  It is recommended to 
have this test every 5 years. The effect of virtual colonoscopy on colorectal cancer 
mortality is unknown.43,44  
iv.  Double-contrast barium enema (DCBE): This test also uses a series of x-ray images 
to view the colon from outside the body. However, an enema with a barium solution 
is given to the patient prior to x-rays. If polyps or other abnormal substances are 
seen, then a colonoscopy is necessary to remove them. This test is not widely used 
in the United States because it is less sensitive compared to a colonoscopy.43,44  
2.1.6.2 Tests that Mainly Identify Colorectal Cancer 
i. Guaiac-based fecal occult blood test (gFOBT): This test detects blood in the stool 
using a chemical reaction. Though blood in the stool can be from cancers and 
 20 
polyps, there are other possible causes such as ulcers, colitis, hemorrhoids. If FOBT 
is the only screening test used by an individual, it is recommended that it be done 
yearly.43,44 Studies show that the gFOBT leads to a decrease in colorectal cancer 
mortality in people aged 50 to 80.44 
ii. Fecal Immunochemical Test (FIT): This is also called an immunochemical fecal 
occult blood test (iFOBT). Like gFOBT, it tests for blood in the stool but uses 
antibodies to detect human hemoglobin protein. 
iii. Stool DNA test (FIT-DNA): A stool DNA test tests for abnormal parts of DNA 
from cancer or polyp cells. Colorectal cancer cells usually have DNA mutations in 
certain genes which are detected by the FIT-DNA. The only FDA approved stool 
DNA test is Cologuard.  
Usually, the test a patient utilizes depends on factors such as age, family history, 
convenience, preferences and medical condition.43,44  
2.1.7 Treatment  
Colorectal cancer treatment depends on the size, location and spread of the tumor. 
Treatments could be local or systemic. Local treatments are therapies that treat the cancer 
without affecting the rest of the body. They include surgery, radiation therapy and ablation. 
Systemic treatments are therapies that reach cancer cells anywhere in the body. They 
include chemotherapy, targeted therapy and immunotherapy.  
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2.1.7.1 Local Therapies 
a. Surgery 
Surgery is the primary treatment for early stage colon cancers. The type of surgery depends 
on the extent of the cancer. Some of the surgical options include polypectomy, colectomy 
and colostomy. 
i. Polypectomy:  In a polypectomy, the cancer is removed as part of the polyp by 
passing a wire loop through the colonoscope to cut the polyp from the colon. A 
local excision is used to remove superficial cancers from the colon wall. 
ii.  Colectomy: A colectomy is a surgery that removes all or part of the colon as 
well as nearby lymph nodes. If only part of the colon is removed, it is called a 
hemicolectomy or partial colectomy. If all of the colon is removed, it is called 
total colectomy. This is usually only performed if there is disease in part of the 
colon without the cancer. A colectomy can be done in two ways: open 
colectomy or laparoscopic colectomy. In open colectomy, a single incision is 
made in the abdomen while laparoscopic colectomy uses several smaller 
incisions and a laparoscope. A laparoscope is a thin lighted tube with a small 
video camera used to view the abdomen.47 
iii. Colostomy: A colostomy is a procedure that involves the use of a surgical 
opening or stoma which is attached to the top end of the colon to provide a path 
for waste (stool) to exit the body into a waste pouch worn by the patient.  
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Side Effects of Colon Surgery 
 In general, the side effects of surgery include pain and tenderness in the site of the 
surgery or in stoma, constipation or diarrhea. Another possible side effect is developing 
scar tissue in the abdomen known as adhesions. This causes organs and tissues to stick and 
could lead to bowel blockade, requiring further surgery.47,48 
b. Radiation therapy 
 Radiation therapy uses high energy X-rays to destroy cancer cells. It is not 
commonly used for colon cancer but may be used to treat cancers that have spread to other 
areas or control cancers in patients who are not healthy enough for surgery. It can also be 
used to palliate symptoms in advanced cancer patients and post-surgery to destroy any 
cancer cells that remain. The three main types of radiation include external beam radiation 
therapy, internal radiation and radioembolization.  
i. External beam radiation therapy is more commonly used for colorectal cancer 
patients. Here the radiation is beamed on the cancer from a machine outside the 
body.  
ii. The internal radiation therapy is usually used to treat rectal cancers and involves 
putting a radioactive substance inside the rectum or close to the tumor with the 
advantage of not having to pass the skin.47 Other types of radiation therapy are 
techniques that can be used to rid the body of cancers not removable via surgery. 
For instance, intraoperative radiation is the use of a high single dose of radiation 
which is administered via surgery. Brachytherapy uses radioactive seeds that 
can be injected into a body organ when surgery is not an option.48 
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iii. Radioembolization is the administration of radiation during an embolization 
procedure.  
Side Effects of Radiation 
 Possible side effects of radiation therapy include skin irritation (redness, peeling) 
at radiation sites, nausea, rectal irritation, bowel incontinence (stool leak), bladder 
irritation, burning while urinating, blood in urine and bloody stools. Also, sexual problems 
such as infertility could occur in both men and women.47,48 
c. Ablation 
 This is often treatment options for people whose cancers cannot be cured with 
surgery or when the cancer has spread to other organs. Ablation destroys tumors without 
removing them from the body. The types of ablation include radiofrequency ablation, 
ethanol ablation and cryosurgery. Radiofrequency ablation uses high energy radio waves 
to destroy tumors. Ethanol ablation is the use of concentrated alcohol injections to destroy 
cancer cells. Cryosurgery is the freezing of a tumor with a thin metal probe and extremely 
cold gasses. 
d. Embolization 
 This is a procedure that involves the injecting of substances into the body to hinder 
blood flow to cancer cells in the liver. It is often used for tumors that are too large to be 
treated with ablation. The three embolization options include arterial, chemo and radio 
embolization. Arterial embolization is the use of a catheter to inject small particles into an 
artery to plug it up. Chemoembolization is a combination of chemotherapy and 
embolization. It is done by giving chemotherapy through the catheter directly into the 
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artery, then plugging up the artery. Radioembolization is a combination of embolization 
and radiation. This is done by injecting small beads coated with a radioactive substance 
into the hepatic artery.  
Side Effects of Embolization 
 Side effects of embolization procedures include belly pain, fever, nausea, liver 
infection and gallbladder inflammation. Also, liver function could worsen because 
sometimes healthy cells are affected in embolization.  
2.1.7.2 Systemic Therapies 
a. Immunotherapy 
 This is the use of medicines to aid the immune system to recognize and destroy 
cancer cells. It is used to treat advanced colorectal cancer. The immune system has the 
ability to not destroy healthy body tissue. It uses checkpoint proteins on immune cells 
to do this. Immune checkpoint inhibitors  (e.g., pembrolizumab and nivolumab) are 
drugs that target and block these checkpoints, thereby boosting immune system 
response against cancer cells to slow their growth.49 
b. Targeted therapy 
 In targeted therapy, specific genes and proteins that contribute to cancer growth and 
survival are targeted and their growth and spread blocked. They can be used alone or 
along with chemotherapy and do have less side effects. Some types include Vascular 
Endothelial Growth Factor Inhibitor (VEGF) inhibitors, and Epidermal Growth Factor 
Receptor (EGFR) Inhibitors.  
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i. VEGF Inhibitors: These inhibit VEGF function, which is to help tumors form 
new blood vessels – a process called anti-angiogenesis. Anti-angiogenesis 
therapies hinder angiogenesis and include bevacizumab (Avastin) which has 
been approved as first line treatment for advanced colorectal cancer, 
regorafenib (Stivarga), ziv-aflibercept (Zaltrap) and ramucicumab (Cyramza).  
ii. EGFR Inhibitors: EGFR inhibitors block EGFR which slows the growth of 
cancer. Examples of drugs here include cetuximab and panitumumab.48,49 
c. Chemotherapy 
 Chemotherapy involves use of anticancer drugs to destroy cancer cells. It can be 
administered systemically or regionally. In systemic chemotherapy, drugs are injected 
into a vein or administered by mouth to reach cancer cells throughout the body. In 
regional chemotherapy, drugs are directly injected into an artery that leads to the tumor. 
The regional method has less side effects because a limited amount of drug is reaching 
the rest of the body. For instance, chemotherapy can be directly injected into the hepatic 
artery (hepatic artery infusion) for a cancer in the liver. Chemotherapy is usually given 
in cycles, with each cycle lasting about 2 to 4 weeks.  Each period of treatment is 
followed by a rest period to enable recovery of the body. Chemotherapy can be 
administered at different times during treatment such as: 
i. Adjuvant chemotherapy: Adjuvant refers to therapy given in addition to the 
main treatment to maximize effectiveness. Adjuvant chemotherapy is given 
post-surgery to destroy cancer cells that were not destroyed during surgery 
due to their small sizes or having settled in other parts of the body away 
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from the main tumor. Adjuvant therapy reduces the chances of cancer 
recurrence.  
ii. Neoadjuvant chemotherapy: This refers to therapy given before the main 
treatment. Chemotherapy could also be given before surgery to shrink the 
cancer and make surgery easier. Neoadjuvant chemotherapy is often done 
in rectal cancer. 
For advanced cancers that have spread to other parts of the body, chemotherapy is 
given to shrink tumors and for palliative purposes. Though this would not likely cure the 
cancer, it can help the patient live longer. Some of the drugs used for chemotherapy could 
be given singly or as a combination of drugs. Chemotherapy drugs could also be combined 
with drugs used for targeted therapy. Some of the drugs used in chemotherapy include 5 
fluorouracil (5-FU), leucovorin or levo-leucovorin, capecitabine (Xeloda), irinotecan 
(Camptosar), oxaliplatin (Eloxatan), trifluridine and tipiracil (Lonsurf).50 
Side Effects of Chemotherapy 
 Drugs used in chemotherapy function by attacking quickly dividing cells in the 
body such as cancer cells. Unfortunately, some normal body cells that are quickly dividing 
get attacked in the process, leading to side effects. Some of the common side effects are 
hair loss, mouth sores, loss of appetite, diarrhea, nausea, vomiting, fatigue, increased 
chance of infections due to low white blood cells, easy bleeding due to low platelets and 
fatigue due to low red blood cells. Additionally, some side effects are specific to certain 
drugs. For instance, hand foot syndrome is common with capecitabine or 5-FU. Neuropathy 
(nerve damage) is common with oxaliplatin. Allergic reactions are also common with 
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oxaliplatin while diarrhea, though a common side effect with most of the drugs, is worse 
with irinotecan.48,50 
2.1.7.3 Treatment Options by Stage  
 Generally, Stages 0, I, II and III of colon cancer are curable with surgery, but 
usually with stage III and sometimes with stage II, patients receive chemotherapy after 
surgery to increase the likelihood of eliminating the cancer. Stage IV is often not curable, 
but tumor growth and symptoms can be managed. For stage 0 colorectal cancer, the 
treatment is a polypectomy (removal of a polyp) during a colonoscopy. For stage I, a 
surgery could be done to remove tumor and lymph nodes. For stage II, surgery is also the 
first line of treatment, and it is sometimes combined with adjuvant chemotherapy. 
Treatment for stage III also involves surgery and sometimes adjuvant chemotherapy. For 
stage IV (metastatic colon cancer), the treatment could include a combination of surgery, 
radiation therapy, immunotherapy and chemotherapy to slow the spread of the cancer and 
also to shrink the tumors.  The goal of surgery here is to relieve blockage of the colon and 
prevent local complications. A resection can also be done, which is a surgery to remove 
parts of other organs that contain cancer in them.   
2.1.7.4 Remission and Recurrence 
 A remission occurs when the cancer can no longer be detected in the body, also 
known as having ‘no evidence of disease,’ or NED. Remission could be partial or complete. 
In partial remission, some of the cancer remains but the tumor is smaller, and the patient 
can stop treatment. In complete remission, the cancer as well as symptoms cannot be 
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detected or measured. Complete remission is usually referred to as NED but does not mean 
the cancer is cured. Also, remissions can be temporary or permanent. However, after five 
years, the cancer can be said to have been successfully managed.  
 Recurrence refers to a cancer that returns after the patient has been in remission. 
This could happen because cancer cells could remain unnoticed in the body for years 
following treatment. If the cancer returns in the same site as before, it is called a local 
recurrence. If cancer returns to a surrounding organ, it is called a regional recurrence and 
if in another place, it is called a distant recurrence. Treatment outcomes usually vary 
widely, but if the cancer cannot be cured or controlled, it is referred to as advanced or 
terminal cancer.48,51 
2.1.8 Economic Burden 
Colorectal cancer imposes a significant economic burden on the society. A study 
that estimated the economic burden of colon cancer hospitalizations using hospital 
discharge data found that the mean total hospital charges were $4.57 billion per year.52 
Another study estimated annual expenditures for colorectal cancer to be $5.3 billion in 
2000, inclusive of both direct and indirect costs.6 
 The total costs of colorectal cancer in 2010 was estimated to be $14.1 billion, 
second only to breast cancer. Amongst cancers, colorectal cancer has the third highest 
mortality costs associated with premature deaths from cancer.53 A study by Zheng et al. 
used Medical Expenditures Panel Survey (MEPS) data to measure excess economic burden 
attributable to colorectal cancer patients. They found that colorectal cancer survivors 
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experience statistically significant higher economic burden compared to individuals 
without a cancer history (P<0.001).54 The results were significant for both the elderly and 
non-elderly population.  
2.1.9 Survival 
Survival for colorectal cancer usually depends on stage of disease at diagnosis. The 
relative survival rate is 65 percent at 5 years after diagnosis and 58 percent at 10 years. By 
site of disease, survival rate ranges from 90 percent 5-year survival rates for localized stage 
cancers, 70 percent for regional, 10 to 14 percent for metastatic cancers.25,30 Overall 5-year 
survival rates are slightly higher for patients with rectal tumors (67%) than for those with 
colon tumors (64%).  Based on tumor location, 5-year survival is higher for patients with 
distal tumors (69%) than for those with proximal tumors (65%). Younger patients also have 
higher survival. The 5-year survival is 69 percent in those younger than 65 and 62 percent 
in those aged 65 years and more.55 Generally, the earlier the stage at diagnosis, the higher 
the chances of patient survival.25 
 The survival for colorectal cancer at all stages have improved significantly since 
the 1960s. Also, survival rates over time have been better in countries with higher life 
expectancy and access to care. And increase in survival rates was higher for whites 
compared to non-whites. Disparities in colorectal cancer survival exist both globally and 
in the United States. Most of the global and regional disparities is likely due to differences 
in access to care.25 In the United States, blacks and American Indians/Alaska Natives 
(AI/AN) have the lowest survival rates for every stage. AIs/ANs are least likely to have a 
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localized stage diagnosis and most likely, together with blacks, to have a distant-stage 
diagnosis. These disparities are attributable to unequal socioeconomic status that results in 
differences in access to early detection and timely and high-quality treatment.30 As of 
January 2016, there were 1.5 million Americans alive with a history of colorectal cancer.55 
2.2 NEUTROPENIA 
Neutropenia is a condition in which the number of neutrophils in the blood is 
significantly reduced, affecting the ability of the body to fight infections.56 The two most 
common blood cells are the red blood cells and the white blood cells. The function of the 
red blood cell is oxygen transport from the lungs to other parts of the body while the 
primary function of the white blood cell is to protect the body from infection.57 The five 
major types of circulating white blood cells include basophils, eosinophils, lymphocytes, 
monocytes and neutrophils.56 Of these, the most common types are the neutrophils and 
lymphocytes. While lymphocytes protect the body against viruses, neutrophils defend the 
body against bacteria. Neutropenia is a situation in which the number of neutrophils in the 
body is too low. Since neutrophils are essential in protecting the body against bacterial 
infections, a patient with neutropenia remains susceptible to bacterial infections.57  
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Figure 2.3: Neutropenia 
 
 Source: https://www.healthnavigator.org.nz/health-a-z/n/neutropenia/ 
 
Clinically, neutropenia is said to occur when the absolute neutrophil count (ANC) 
is less than 1500 per microliter (1500/µL).56 Generally, the blood of a healthy adult 
contains about 1500 – 7000 neutrophils/µL.57  The ANC is calculated by multiplying the 
total white blood cells by the portion of neutrophils among the white blood cells as 
determined by white blood cell differential analysis. Other factors such as age, race, 
genetics and environmental factors can affect neutrophil count. For instance, blacks may 
have a lower ANC value of 1000 cells/µL with a normal total white blood cell count. Based 
on the ANC, neutropenia may be classified as mild, moderate or severe. Neutropenia is 
said to be mild when the ANC ranges 1000 – 1500/µL, neutropenia is moderate when the 
ANC ranges 500 – 1000/µL and severe neutropenia occurs when the ANC is less than 
500/µL.58  
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 A number of medical terms are sometimes used interchangeably with neutropenia, 
even though their exact definitions differ. Leukopenia is a decreased number of white blood 
cells in general, while granulocytopenia is a reduced number of all granulocyte type blood 
cells which include neutrophils, eosinophils, and basophils. Given that neutrophils are the 
most numerous among the granulocytes, granulocytopenia is sometimes used to refer to 
neutropenia. On the other hand, agranulocytosis refers to a total absence of all 
granulocytes. And this is also sometimes used interchangeably with severe neutropenia.56 
It usually refers to cases where the ANC is less than than 100/µL.58  
2.2.1 Pathophysiology 
Neutrophils are made in the bone marrow and released into the bloodstream. Most 
neutrophils in the body are contained in the bone marrow. The entire neutrophil content in 
the body can be divided into 3 sections: the bone marrow, the blood and the tissues. In the 
bone marrow, neutrophils could exist in two divisions: the mitotic section and the 
maturation-storage section. Neutrophils exit the marrow storage section and enter the blood 
without going back to the marrow. Then they leave the blood randomly after 6 – 8 hours 
and enter the tissues where they are destined for cellular action or death.58 The mature 
neutrophil has a lifespan of about 3 days.56  
 Neutropenia is associated with an increased risk of bacterial infections in patients, 
and the risk depends on its cause and severity. Generally, infection risk increases as ANC 
decreases. The duration and severity of neutropenia is directly correlated with total 
incidence of all infections and life-threatening infections. When the ANC is consistently 
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lower than 100 cells/µL for longer than 3-4 weeks, then incidence of infection gets closer 
to 100 percent. At this point, life threatening infections and sepsis could occur.58  
2.2.2 Etiology 
The etiology of neutropenia could be categorized via mechanism or etiology. The 
mechanism that lead to neutropenia are not well understood. Usually neutropenia happens 
after a long-term exposure to some medication or other substances which results in 
decreased neutrophils produced by the bone marrow. In other instances, a repeated but 
intermittent drug is required though the exact exposure as related to neutropenia is 
unknown.  
 On the other hand, categorization via etiology is grouped as either congenital or 
acquired. Congenital neutropenia is hereditary and most occur due to mutations in the gene 
encoding neutrophil elastase, ELA2. The acquired neutropenia are mostly related to any of 
three broad categories: autoimmune, infection and drugs. Chronic benign neutropenia (also 
called chronic idiopathic neutropenia) is an overlap disorder with both hereditary and 
acquired forms.  
2.2.2.1 Congenital Neutropenia 
Congenital neutropenia with associated immune defects occurs when an individual 
has neutropenia with abnormal immunoglobulins. Congenital or chronic neutropenia is 
caused by a recessive gene and is often recognized at birth or shortly afterwards. Cyclic 
neutropenia is characterized by sessions of neutropenia and infection usually in infants or 
children. Chronic benign neutropenia usually occurs with overall low risk of infection. 
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Chronic idiopathic severe neutropenia can occur in both children and adults and is a 
diagnosis of exclusion. Neutropenia associated with phenotypic abnormalities include 
Schwachman syndrome, Barth syndrome and Chediak-Higashi syndrome. Other 
congenital neutropenia includes lazy leukocyte syndrome which is a severe neutropenia 
with associated abnormal neutrophil motility and myelokathexis that is characterized by 
moderate neutropenia and recurrent infections and usually presents in infancy. 
2.2.2.2 Acquired Neutropenia   
Acquired neutropenia can be caused by intrinsic bone marrow disease, infection, 
nutritional deficiency, drugs and chemicals, or could be immune mediated.  
i. Bone marrow disease: Inherent bone marrow sicknesses that could lead to 
neutropenia include aplastic anemia, ionizing radiation, tumor infiltration, 
myelofibrosis, granulomatous infection and hematologic malignancies such as 
leukemia, lymphoma and myeloma. 
ii. Immune-mediated: Immune-mediated neutropenia could be caused by drugs 
(e.g., quinidine, penicillins, sulfonamides, cephalosporins) that induce antibody 
formation in the body. These antibodies destroy granulocytes and the drug 
could form immune complexes that attach to neutrophils.  
In autoimmune neutropenia, the body makes antibodies to destroy neutrophils 
and could be associated with the following diseases: Crohn’s disease, 
rheumatoid arthritis, Hodgkin lymphoma, chronic autoimmune hepatitis, 
systemic lupus erythematosus and pure red blood cell aplasia. 
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iii. Infection-related: The most common form of acquired neutropenia is via 
infection.    Some of the infections that could cause neutropenia include 
bacterial sepsis, typhoid, tuberculosis, malaria, dengue fever and viral 
infections such as influenza, measles and viral hepatitis.  
iv. Nutritional deficiency: Some of the nutritional deficiencies that could cause 
neutropenia consist of Vitamin B12, folate and copper deficiencies.  
v. Drugs and Chemicals (apart from cytotoxic chemo): Several drugs have been 
associated with neutropenia with the greatest risk being with antithyroid 
medications, macrolides and procainamides. Some drugs could cause 
neutropenia by acting via an immune-mediated mechanism while other drugs 
have direct harmful effects on the bone marrow cells or on neutrophil precursors 
in the mitotic compartment. In addition, other drugs could have a combination 
of immune and nonimmune mechanisms or could have mechanisms of action 
that are not known.  
Drug and chemical exposure most commonly leads to agranulocytosis. Drugs 
that cause bone marrow depression or aplasia are capable of causing 
agranulocytosis. Some of the drugs frequently associated with agranulocytosis 
include phenothiazine, antithyroids, sulfonamides, aminopyrine and 
chloramphenicol.  
vi. Miscellaneous Immunologic-related: Immunologic neutropenia could occur 
after a bone marrow transplantation and blood product transfusions.58 
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vii. Cytotoxic chemotherapy: Neutropenia could occur as a side effect of 
chemotherapy. This happens when myelosuppressive chemotherapeutic 
treatment reduces the ANC.59 
2.2.3 Chemotherapy Induced Neutropenia 
Chemotherapy and radiotherapy are known to be major causes of neutropenia and 
febrile neutropenia.60 Neutropenia is a common toxicity of chemotherapy caused by bone 
marrow suppression. Chemotherapeutic drugs work by destroying rapidly growing cells, 
which is a characteristic of cancer cells. However, it also affects normal cells that grow 
rapidly in various parts of the body such as bone marrow, hair follicles, mouth, etc. 
Furthermore, chemotherapy drugs affect the production of folic acid as well as the 
synthesis of DNA, RNA and protein by acting as antimetabolites, causing bone marrow 
destruction. Some drugs that are highly associated with neutropenia include asparaginase, 
cytarabine, cisplatin, busulfan and methotrexate. Some studies have found a significant 
relationship between neutropenia and chemotherapy drugs. Buffoni et al. found that the 
combination of chemotherapy drugs cisplatin and vinorelbine, though highly effective, was 
associated with febrile neutropenia which was fatal in some of the study subjects.61 
Likewise, Banerji et al. found the combination of chemotherapy drugs etoposide and 
carboplatin to be significantly associated with neutropenia.62 However, different 
chemotherapy regimens are not associated with the same severity of neutropenia. Research 
suggests that neutropenia is associated with the regimen intensity.63 While high or intensive 
chemotherapy medications may lead to neutropenia or even severe neutropenia, low 
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chemotherapy doses may cause other adverse effects such as nausea, alopecia, 
thrombocytopenia, anemia and vomiting.60,64 
 Chemotherapy administration could follow either of two routes: systematic which 
includes intravenous (IV), oral and intramuscular (IM) or local which includes intrathecal, 
intraperitoneal, intra-arterial and intrapleural. Of these, IV and oral are most commonly 
used. This is due to the advantage of the drug reaching tumor cells throughout the body. 
These routes (IV and oral) also have the disadvantage of reaching and destroying other 
body tissues, hence causing increased side effects. Therefore, the primary goal of IV 
chemotherapy is to achieve a systematic concentration that is effective for the cancer.60  
 Chemotherapy induced neutropenia usually occurs 3 to 7 days after administration 
of chemotherapy and continues until ANC levels return to normal. The chemotherapy 
regimen affects how the neutrophil count drops and length of the illness and recovery. 
Chemotherapy induced neutropenia increases the risk of life threatening infections in a 
patient and could disrupt chemotherapy. This disruption in chemotherapy could reduce the 
chances of a patient’s cure or survival. However, neutropenia could be prevented via use 
of certain medications.65  
2.2.4 Epidemiology 
The average incidence of neutropenia in the United States is 56.4 per million 
people. Generally, neutropenia occurs in 1 out of 3 patients treated with chemotherapy. 
There are very few studies that give an exact number on neutropenia prevalence.60 The 
estimated frequency of agranulocytosis is 1.0 – 3.4 cases per million persons per year.  
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 There is a higher incidence of neutropenia in the elderly compared to younger 
individuals. However, agranulocytosis occurs across all ages. Neutropenia occurs more 
frequently in women than in men. However, agranulocytosis occurs slightly more 
frequently in women than men. Blacks, Ethiopians and certain populations could have 
lower ANCs as a result of lower white blood cell counts. Analyses from the National Health 
and Nutritional examination survey showed the prevalence of neutropenia to be 4.5 percent 
among blacks, 0.79 percent in whites and 0.38 percent in Mexican-Americans.58 
 Studies show that neutropenia is associated with solid tumors particularly breast 
cancer, as 25 percent of breast cancer patients develop neutropenia. Of patients with solid 
tumors, breast cancer patients have the highest risk for developing severe neutropenia and 
febrile neutropenia during their first cycle of chemotherapy.60 
2.2.5 Predisposing Factors 
The risk factors for neutropenia include patient-related, treatment-related and 
disease-related factors. Among the patient-related factors, being female is a risk factor for 
neutropenia. A systematic review of risk factors for febrile neutropenia showed female 
gender to be a risk factor for developing febrile neutropenia or being hospitalized for febrile 
neutropenia.66 In another study, gender was found to be significantly associated with 
neutropenia severity as well as neutropenia complications.67 
 Also, neutropenia is more common among individuals aged 50 years or older. 
Compared to young people, older individuals are less able to produce mature neutrophil 
cells due to age. The systematic review by Lyman et al. found age to be a risk factor for 
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febrile neutropenia, as well as febrile neutropenia related hospitalizations.66 Ethnicity has 
been linked to neutropenia. Hershman et al. found an association between ethnicity and 
neutropenia among cancer survivors with white blood cell levels in African American 
women being significantly lower than among white women.68 Similarly, studies 
demonstrate that comorbid conditions with cancer is a risk factor for febrile neutropenia. 
The risk of febrile neutropenia increases in direct proportion to the number of comorbidities 
a patient has. 69,70 
 The treatment-related factors include chemotherapy regimen and prophylaxis for 
neutropenia. Several studies suggest that certain chemotherapy regimen and dose intensity 
of the regimen are significant predictors of febrile neutropenia and febrile-neutropenia 
related hospitalization,71-73 especially given that some chemotherapy medications are more 
myelosuppressive than others. On the other hand, patients who receive primary prophylaxis 
with G-CSF have been shown to be at a lower risk of febrile neutropenia and related 
hospitalizations, and this holds across various forms of cancers.15,71,72 
 For the disease-related factors, the type of tumor, having an advanced disease as 
well as genetic factors have been pinpointed as risk factors for neutropenia.66  
2.2.6 Signs and Symptoms 
Neutropenia itself does not present with symptoms but leads to an increased 
susceptibility to infections in individuals. The symptoms noted are often symptoms of an 
infection or the underlying cause of the neutropenia. Usually, patients who undergo 
chemotherapy are at an increased risk and therefore undergo routine blood tests to test for 
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neutropenia. The infections can appear as ulcers, rashes and abscesses. In most patients, 
fever is the only symptom. Other signs of an infection include high fever, malaise, flu-like 
symptoms, abdominal pain, diarrhea and vomiting, sore throat, mouth sores, coughing, 
increased urination and troubled breathing.13 
2.2.7 Diagnosis 
Neutropenia is diagnosed using a complete blood count test. The complete blood 
count involves measuring the amount of neutrophil in the blood. If the neutrophil count is 
low, tests may be repeated to be certain. Following the blood test, a bone exam (bone 
marrow aspirate) may be carried out to confirm presence of neutropenia. This involves 
obtaining bone marrow aspirates from for a bone biopsy.60 It can also diagnosed via 
cytogenetic evaluation and molecular testing.57  
2.2.8 Management 
2.2.8.1 Prevention 
With certain chemotherapy regimens, preventing neutropenia is difficult or even 
impossible. However, some measures can be taken to help prevent or reduce the duration 
or severity of neutropenia. Generally, in cancer patients, neutropenia is managed by 
chemotherapy dose reduction, dose interval delays, initiation of primary or secondary 
prophylaxis using hematopoietic growth factors, also called recombinant granulocyte 
colony-stimulating factors (G-CSF), based on individual febrile neutropenia risk 
assessment and chemotherapy regimen.74  
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i. Chemotherapy dose modification: Reducing the dose of chemotherapy could help 
reduce neutropenia. The disadvantage of dose reduction is that it affects the dose-
response relationship of the drug. While decreasing doses may prevent neutropenia, 
drug efficacy may also be decreased. This option is most relevant for patients on 
palliative care, not curative treatment. Also, dose intervals can be delayed or 
modified.75  
ii. Growth Factors (Primary prophylaxis): Primary prophylaxis using G-CSFs can be 
initiated. The oldest G-CSF is filgastrim, while a longer acting one is pegfilgastrim. 
However, patients must be individually and appropriately selected based on risk 
assessment of febrile neutropenia and chemotherapy regimen.74 The ASCO has 
published guidelines on use of these growth factors based on patient risk level. 
There is evidence that CSFs can prevent up to 50 percent of neutropenic fevers.76-
78 Studies have shown that the risk of febrile neutropenia is highest at the first cycles 
of chemotherapy.79,80  
iii. Growth Factors (Secondary Prophylaxis): Patients with neutropenic fever are at a 
higher risk to develop it again in subsequent therapy. Usually, secondary 
prophylaxis is administered especially if dose reduction is unfavorable for the 
patient.75  
iv. Antibiotics: Prophylactic antibiotic therapy can be administered. However, there is 
a possibility of developing resistance to antibiotics.75 But a combination of 
neutropenia and having a gram negative bacterial infection is associated with a high 
mortality. Therefore, antimicrobial therapy must be started as a mono antibiotic 
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therapy or combination therapy. Empirical antibiotics used must be broad spectrum 
to cover most potential pathogens. The three widely used antimicrobial strategies 
for treating febrile neutropenia include: (1) a combination of beta-lactam with 
aminoglycoside; (2) monotherapy with a wide range beta-lactam; and (3) both 
strategies combined. Generally, several antibiotics may be used to treat 
neutropenia. Though, only a few of them are effective in the treatment of febrile 
neutropenia. For instance, ceftazidime is one of the most effective antibiotics and 
is approved for the treatment of febrile neutropenia in patients of different ages.  
v. Other therapies: Antifungal and antiviral drugs can also be administered during 
treatment depending on type of microbial infection. Neutropenia is associated with 
infections which can be bacterial, fungal or viral in origin.60 
2.2.8.2 Treatment 
When neutropenia is associated with fever, it is called febrile neutropenia. When 
this occurs, treatment is necessary due to an increased inability of the body to fight 
infections. Hospitalization and administration of broad spectrum antibiotics are necessary 
until the patient recovers an adequate neutrophil count.74  
2.2.9 Prognosis 
The prognosis of neutropenia depends on the cause, duration and severity of the 
neutropenia. Due to improved care and improved broad-spectrum antibiotic agents, the 
prognosis for patients with neutropenia has improved. However, patient survival depends 
on recovering a sufficient number of neutrophils. Deaths related to neutropenia often 
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involve infections during severe episodes of neutropenia and usually correlate with 
duration and severity of neutropenia. Severe medical complications occur in about 21 
percent of patients who have cancer and neutropenia.81-83 Three known high-risk subgroups 
of cancer patients with febrile neutropenia include: inpatients with fever while developing 
neutropenia, outpatients who require acute care and stable outpatients with uncontrolled 
cancer.  
 Drug induced agranulocytosis has a mortality rate of 6-10 percent. Untreated 
agranulocytosis causes a high risk of mortality but prompt treatment leads to an improved 
prognosis.58 
2.2.10 Economic Burden 
Neutropenia as well as febrile neutropenia impose an economic burden on patients 
and society.  Previous studies estimate that each year in the United States, over 60,000 
cancer patients are hospitalized due to neutropenia, of which 4,000 die of febrile 
neutropenia.84 Tai et al.’s 2012 study using a nationally representative sample showed that 
91,560 adults and 16,859 children were hospitalized due to neutropenia. The total cost for 
hospitalizations for adults was $2.3 billion, and $439 million for children, which represents 
8 percent and 27 percent of all cancer-related hospital costs for adults and children, 
respectively. Adult cancer patients who were hospitalized for neutropenia stayed longer on 
average and paid about $5700 more than adult cancer patients who were hospitalized for 
other reasons. Individuals who were hospitalized for neutropenia were more likely to be 
admitted via the emergency room than individuals who were treated for other reasons.85 
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One study that assessed the economic burden of colorectal cancer patients with febrile 
neutropenia showed a mean hospitalization cost of $19,667 in 2010.86  
2.3 FEBRILE NEUTROPENIA 
Febrile neutropenia refers to neutropenia with fever. It is characterized by a 
decrease in body neutrophil count below 500cells/mm3 and the occurrence of fever.87 Fever 
is defined as a rise in auxiliary temperature (>=38.5C) sustained for at least 1 hour.88 It is 
a usual occurrence in cancer patients due to their chemotherapy regimens. Neutropenic 
fever is typically associated with infections caused by microorganisms including bacteria, 
fungi and viruses. However, severe infections are most commonly seen with gram negative 
bacteria although gram positive bacteria can cause life threatening infections as well.  
 Though any type of neutropenia can become febrile, it is most common in cancer 
patients undergoing therapy. Thus, cancer patients are routinely screened for febrile 
neutropenia. It is diagnosed by a physical examination for fever and a complete blood count 
test for neutropenia.87  
2.3.1 Epidemiology 
The incidence of febrile neutropenia in the United States is estimated to be 60,294 
per year including 7.83 cases per 1000 cancer patients. However, the incidence is higher 
(43.3 cases per 1000 individuals) in persons who suffer hematological malignant tumors. 
Incidence of febrile neutropenia varies depending on cancer type, chemotherapy regimen, 
age, sex and antibiotic treatment.87 
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Over the years, the morbidity and mortality rates of febrile neutropenia have 
decreased due to appropriate treatment, care and preventive measures. Fifty percent of 
mortality in patients receiving chemotherapy for solid tumors has been attributed to febrile 
neutropenia. Also, in patients receiving chemotherapy for acute leukemia, febrile 
neutropenia related infections cause 50 percent to 75 percent of deaths. The rapid and 
effective use of antibiotics has reduced associated mortality to 10 percent. In the United 
States, mortality rates of 6.8 percent to 9.5 percent have been reported. In patients with 
solid tumors and hematological malignancies, mortality rates are at 5 percent and 11 
percent, respectively. Mortality rates increase to 15 percent in patients with gram-negative 
bacteria, whereas gram-positive bacteria account for 5 percent. Elderly patients are at a 
higher risk of febrile neutropenia and have higher morbidity and mortality.87  
2.3.2 Consequences 
Febrile neutropenia is often associated with complicated infections and is seen as 
an oncologic emergency. It poses a significant threat to patient survival and this threat is 
worsened if there is a persistent occurrence of antibiotic resistant microorganisms which 
causes infections that are difficult to manage. The most serious infections are associated 
with gram-negative bacteria and are usually life-threatening. However, other infections 
caused by gram-positive bacteria, as well as viral and fungal infections can be dangerous 
and can lead to significant morbidity and possibly mortality. In patients with neutropenia 
without fever, neutropenia leads to chemotherapy delays, and/or dose modifications which 
can affect patient outcomes and survival.  
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 Neutropenic colitis, also known as typhlitis is another serious complication of 
neutropenia. It is characterized by fever and abdominal pain. It is more common in 
hematological malignancies and are often treated with antibiotics. Sometimes, acute 
surgery may be required if there is concern for the ischemic bowel.74  
2.3.3 Risk Assessment 
The risk of developing fever is the most important factor that determines how CSFs 
will be used.89 It is recommended that the physician assesses the patient’s risk at the start 
of chemotherapy, by determining their regimen and individual risk factors.90 Patients with 
neutropenia can be categorized based on risk of complications into three categories: high 
risk (>20%), intermediate risk (10-20%) or low risk (<10%). The risk assessment is used 
to develop a management plan for patients. The National Comprehensive Cancer Network 
(NCCN) and other bodies have issued guidelines for the stratification of risk of febrile 
neutropenia.87 The Multinational Association of Supportive Cancer (MASCC) risk index 
score is a validated tool that can be used to predict patient risk of developing complications. 
The tool consists of 8 items that can be assessed to assign risk. Patients with a score of 21 
or more are considered low risk while patients with lower scores are considered high risk 
and require more intensive management. Although there are other tools in use for the same 
purpose, the MASCC tool has been externally validated.74 
2.4 COLONY-STIMULATING FACTORS (CSFS) 
CSFs are medications that help the body produce white blood cells. They are 
glycoproteins produced by the body as well as made in the laboratory. They are also called 
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white blood cell growth factors or hematopoietic (blood-forming) growth factors. Cancer 
patients undergoing chemotherapy usually have low numbers of white blood cells as a 
result of cancer drugs which increase the risk of infections. White blood cells are used by 
the body to fight infections but are destroyed in cancer treatment, leading to neutropenia 
or febrile neutropenia.  
 CSFs are supportive drugs. They are not effective on cancer cells and therefore do 
not cure cancer. Rather they are used to prevent or lessen infections by stimulating the bone 
marrow, leading to an increased production of blood cells which strengthens the immune 
system. They are given as injections, usually 24 hours after a chemotherapy treatment.16 
2.4.1 Biology 
CSFs regulate granulocytes and macrophages in the body. Granulocytes and 
macrophages are part of the immune system and protect the body against infections. 
Mostly, these cells have a short life and need to be continually replaced by new cells. As 
long as the individual remains in good health, the cell numbers remain constant. However, 
the body produces these cells in response to demand. In the presence of an infection, 
production of granulocytes and macrophages can be highly increased. The flexibility to 
respond to urgent demands by the body requires a highly responsive control system. CSFs, 
in a group of 4 glycoproteins, help the body achieve the competing demands for stability 
and flexibility in cell production. The CSFs belong to a group of regulatory factors known 
as cytokines. Sometimes the CSFs interact with other cytokines synergistically in the 
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control system. Also they can interact with some bone marrow cells in the control of the 
formation of stem cells which are early precursors of granulocytes and macrophages.17 
2.4.2 Actions 
The CSFs are glycoproteins with molecular weight ranging from 18 to 70,000. They 
have a short half-life of a few hours in vivo and can be produced either locally at the site 
of infection or systemically by multiple tissues. The CSF control system responds promptly 
to changing demands. The five major actions of CSFs on responding granulocyte-
macrophage cells include: (1) preventing cell death by blocking apoptosis; (2) stimulating 
cell division in a dose-response manner which determines cell count; (3) influencing the 
lineage-commitment choices of cells; (4) initiating and maintaining cell maturation; and 
(5)  stimulating the actions and functions of mature end cells.17 
 In addition, the CSFs have an influence on all bone-marrow derived cells such as 
erythrocytes, monocytes, Langerhans cells, megakaryocytes, lymphocytes, eosinophils and 
mast cells. These cells require such interactions to be fully mature and functional. They are 
stimulated by the CSFs which enable them to differentiate and mature.91  
2.4.3 Types of CSF Medications 
Though CSFs are naturally produced in the body, they can also be produced using 
recombinant DNA technology in laboratories. The 4 distinct types of CSF include: (1) 
Granulocyte Colony-Stimulating Factor (G-CSF); (2) Macrophage Colony-Stimulating 
Factor (M-CSF); (3) Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF); and 
(4) Multipotential Colony-Stimulating Factor (Interleukin (IL) -3]. The FDA licensed G-
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CSF and GM-CSF for use in chemotherapy induced neutropenia and marrow damage as 
they have been demonstrated to be effective for this purpose. Of them, G-CSF is more 
widely used and has alone, been used to manage 10 – 20 million patients with cancer or 
neutropenia.17 
1. G-CSF: G-CSFs stimulate the production of neutrophils, a type of granulocyte. G-
CSFs are the most important regulators of neutrophil production levels. They are 
primarily used for chemotherapy induced and nonmalignant neutropenia. G-CSFs 
work by reducing the time of transition from stem cell to mature neutrophil, leading 
to a large amount of functional and mature neutrophils circulating in the body.89 
Some of the brands available include filgastrim (Neupogen) and pegfilgastrim 
(Neulasta). Filgastrim is the most commonly used G-CSF. The typical dose for 
Neupogen is 5 mcg/kg daily. The typical dose for Neulasta is 6mg once per 
treatment cycle. Globally, several biosimilars of filgastrim have been approved 
with some still in development. 
2. GM-CSF: GM-CSFs stimulate the production of two types of white blood cells, 
both neutrophils and macrophages. The available GM-CSF is sargramostim 
(Leukine). The dose for Leukine is 250mcg/m2 daily. 92 
3. M-CSF: M-CSFs stimulate the production of macrophages. Loss of MCS has the 
greatest effect in reducing monocyte and macrophage population in organs. 
However, due to a side effect of thrombocytopenia, it has not entered the clinic.  
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4. Interleukin 3 (IL-3): Loss of IL-3 has a minor effect on the population of 
granulocytes or macrophages but decreases mast cell levels and some T-cell 
responses. However, it has not been licensed for use due to side effects.91 
2.4.4 Clinical Uses  
CSFs are used to treat hematological diseases and infections. Most clinical trials 
that studies CSFs have involved GM-CSF, which are used to treat Human Immuno-
deficiency (HIV)-related illnesses, aplastic anemia and cancer. G-CSFs have been used to 
treat chemotherapy induced and non-malignant neutropenia.  
i. HIV-related illnesses: Persons with HIV infections could have abnormal 
functioning of their white blood cells. The initial clinical trial of GM-CSF was in 
patients with acquired immunodeficiency syndrome (AIDS) who were neutropenic. 
The study showed a double increase in their leukocyte counts, with the most 
significant seen in neutrophils and eosinophils. However, there are concerns that 
GM-CSF leads to possible HIV replication as seen in some in vitro studies.93 
ii. Aplastic anemia: CSFs lead to modest neutrophil increases in patients with aplastic 
anemia. Patients who have severe disease with no evidence of residual 
myelodysplasia may not respond to GM-CSF. 
iii. Myelodysplastic Syndrome:  This refers to a group of diseases or disorders that 
occur due to blood cells that fail to mature or function properly. Trials that have 
used GM-CSF report an improved neutrophil count and hematologic 
improvement.94,95 
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iv. Cancer therapy: GM-CSF has been shown to improve neutropenia after 
chemotherapy in patients with metastatic sarcoma,96 as well as patients with various 
solid tumors.97 Some of the benefits noted include significant decreases in febrile 
neutropenia, mucositis and need for antibiotic use.97 Also, both G-CSF and GM-
CSF have been used in trials in patients undergoing high-dose chemotherapy with 
autologous bone marrow transplant for various cancers such as metastatic breast 
carcinoma, malignant melanoma, Hodgkin lymphoma and non-Hodgkin 
lymphoma. And across all conditions, neutropenia was reduced, and febrile 
episodes were fewer.94,97  
v. Nonmalignant neutropenia: G-CSF have been used in patients with cyclic 
neutropenia, chronic idiopathic neutropenia and congenital agranulocytosis. In 
cyclic neutropenia, use of G-CSF has been shown to increase average neutrophil 
counts.98 Patients with congenital agranulocytosis have shown continued increases 
in neutrophil counts and decreased need for antibiotics.99 Also, G-CSF has been 
shown to normalize neutrophil counts in patients with chronic idiopathic 
neutropenia.100 
vi. Miscellaneous uses: GM-CSF can potentially be used in accidents caused by 
radiation.91 
2.4.5 Adverse Effects  
Although receiving CSF medications helps reduce hospital admissions and length 
of stay, they also have some risks and adverse effects.  With short acting formulations, 
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multiple injections are required to deliver the medication. Also, CSFs can cause low-grade 
fever, headaches, nausea, myalgias and bone pain. Bone pain in the ribs, sternum and back 
are typically reported with G-CSF and GM-CSF.  However, the pain occurs because the 
bone marrow is making more blood cells.16,91  
 More serious adverse effects have included hypokalemia, hypotension, pulmonary 
infiltrates, and capillary leak syndrome though most of these effects occurred at higher 
doses of GM-CSF.91 Other possible complications include hematological complications 
such as acute arterial thrombosis, thrombocytopenia, anemia, myeloid leukemia and sickle 
cell crisis. Some dermatological side effects associated with filgastrim include alopecia, 
generalized maculopapular rash, reversible acne, and acute febrile neutrophilic dermatosis. 
Some gastrointestinal effects include diarrhea, mucositis, anorexia, constipation, sore 
throat and stomatitis.89 
 
2.5 EFFECTS OF CSF USE IN ONCOLOGY  
CSFs are used in cancer patients undergoing chemotherapy in three different ways: 
primary prophylaxis, secondary prophylaxis and therapeutic purposes. Primary 
prophylaxis is usually administered during the first cycle of chemotherapy to prevent the 
occurrence of neutropenia. Secondary prophylaxis is usually administered after a patient 
already has neutropenia and it is given to prevent a future occurrence. Therapeutic CSF is 
administered for treatment purposes. The incidence of neutropenia is highest in the first 2 
cycles of first course chemotherapy and is associated with more neutropenic events in later 
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cycles. Thus, primary prophylaxis of CSF has a synergistic effect in preventing future 
neutropenic episodes. Furthermore, secondary prophylaxis in subsequent cycles is usually 
too late to prevent neutropenia.9 
2.5.1 Primary Prophylaxis  
There is substantial evidence on the effect of primary prophylaxis in preventing 
neutropenia. Several clinical trials over the years have shown the effectiveness and 
efficacy.101 The guidelines by ASCO are evidence-based, culling from clinical trials on the 
effectiveness of CSF for primary prophylaxis.18 Meta analyses of randomized controlled 
trials (RCTs) conducted in different patient populations confirmed that primary 
prophylaxis with CSF reduces the risk of febrile neutropenia during chemotherapy for a 
solid tumor.15,102,103 It also reduces the risk of hospitalization and infections.104,105 
2.5.2 Secondary Prophylaxis  
Sometimes a patient who is not at risk for administration of primary prophylaxis 
suffers neutropenia in a chemotherapy cycle. Secondary prophylaxis could then be 
administered. However, evidence is lacking on the effectiveness of CSFs in such situations. 
Mostly, chemotherapy dose reduction or delay is a rational option.101 But secondary 
prophylaxis is still supported for patients in which dose reduction could lead to unfavorable 
outcomes in terms of a disease-free survival or overall survival.18 
2.5.3 Treatment 
The effectiveness of routine use of CSF for therapeutic purposes has not been 
established as there is limited evidence on its clinical benefits.106 A 2002 study found no 
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statistically significant advantage of use of CSF in terms of mortality from FN.106 Another 
study found no decrease in overall mortality rates between febrile neutropenia patients 
treated with antibiotics plus CSF compared patients treated with antibiotics alone.107 Thus, 
CSF use for therapeutic reasons is not recommended for patients with afebrile neutropenia 
by all existing clinical guidelines. However, ASCO recommends that it can only be used 
in febrile neutropenia when the patient has a high risk of FN or prognostic factors that lead 
to unfavorable clinical outcomes.18   
2.6 GUIDELINES FOR CSF USE  
Clinical practice guidelines for the utilization of CSFs in patients with neutropenia 
have been developed by several professional and international oncology organizations, 
using evidence from RCTs and meta-analysis. Some of the bodies include American 
Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN), 
and European Organization for the Research and Treatment of Cancer (EORTC). The 
initial guideline by ASCO was published in 1994, and was subsequently updated in 1996, 
1997, 2000 and 2006, with the most recent being the 2015 update.108 The NCCN guideline 
on the use of myeloid growth factors was first published in 2005 with the latest in 2014.109 
The EORTC published guidelines on use of CSF in adults with lymphomas and solid 
tumors in 2006, with an update in 2010. The EORTC current guidelines were planned to 
complement the European Society for Medical Oncology (ESMO) guidelines on use of G-
CSF for prevention of chemotherapy induced febrile neutropenia in patients with cancer.88 
The focus of this study will be on the ASCO guidelines.  
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2.6.1 2015 ASCO Guidelines   
The ASCO recommendation was a response to problems of costs and adverse 
events associated with CSF use. The guidelines address the strengths and limitations of 
CSF use in a wide range of clinical practice settings and were based on a thorough review 
of evidence.18  
The recommendations are as follows:   
Recommendation 1: Primary prophylactic CSF use starting from the initial chemotherapy 
and continuing through following cycles is recommended for patients who have a 20 
percent or higher risk of febrile neutropenia, based on individual, tumor and treatment 
related factors. However, effective and safe alternative chemotherapy regimens should be 
considered.  
Recommendation 2: Secondary prophylactic use of CSF is recommended for patients who 
already had a neutropenic complication from a prior chemotherapy cycle (where primary 
prophylactic CSF was not given) in which a reduced dose or treatment delay could 
compromise survival and outcomes. However, reduced dose and treatment delay could be 
a rational alternative.  
Recommendation 3: CSFs should not be regularly administered for cancer patients with 
neutropenia who are not febrile. Also, CSFs should not be administered regularly as 
adjunctive treatment with antibiotics in patients with febrile neutropenia. However, CSFs 
may be used for patients with febrile neutropenia who have an increased risk of infections. 
Recommendation 4:  Chemotherapy dose-dense regimens with CSF support should only 
be used in a well-designed clinical trial, or if backed by substantial efficacy data. Though 
efficacy data supports administering dose-dense chemotherapy in adjuvant treatment of 
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high-risk breast cancer, there is limited evidence to support its use in non-Hodgkin 
lymphoma, hence it is not routinely recommended. [Dose-dense regimen refers to a 
chemotherapy treatment plan in which drugs are administered with less time between 
treatments than with a standard treatment.]  
Recommendation 5: For the purpose of progenitor cell transplantation, CSFs may be 
administered alone, following chemotherapy, or combined with plerixafor. CSFs should be 
given after autologous stem cell transplantation to reduce the duration of severe 
neutropenia. CSFs may be administered after allogeneic stem cell transplantation to reduce 
the duration of severe neutropenia.  
Recommendation 6: CSFs should be not be used in patients receiving concomitant 
chemotherapy and radiation therapy. If no chemotherapy was given, CSFs may be used 
therapeutically in patients receiving radiation alone if prolonged delays secondary to 
neutropenia are expected.  
Recommendation 7: [Use in the elderly] Prophylactic CSFs should be considered for 
patients with diffuse aggressive lymphoma who are 65 years or older treated with curative 
chemotherapy, especially if the patient has comorbidities.  
Recommendation 8: [Use in Pediatric population] The use of CSF in children should be 
guided by clinical procedures. Like in adults, CSF can be administered as primary or 
secondary prophylaxis for pediatric patients at high risk of febrile neutropenia. For 
pediatric situations in which dose intense chemotherapy is known to be beneficial, CSFs 
should be used to allow the administration of these regimens.  
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Recommendation 9: Pegfilgastrim, filgastrim, tbo-filgastrim and filgastrim-sndz (and other 
biosimilars) are recommended for preventing of treatment-related febrile neutropenia. The 
choice of agent a patient uses depends on cost, convenience or clinical situations.  
Recommendation 10: Patients who have been exposed to lethal doses of total-body 
radiotherapy which are not fatal should be administered CSFs or PEGylated G-CSFs. 
Factors that are considered risk factors for febrile neutropenia can be found in Table 2.2. 
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Table 2.2: Patient Risk Factors for Febrile Neutropenia  
Risk Factors to Be Considered when estimating Patient’s Risk 
 
 Age equal to or above 65 years 
 Advanced tumor 
 Previous chemotherapy or radiation therapy 
 Preexisting neutropenia or bone marrow involvement with tumor infection 
 Open wounds or recent surgery  
 Poor performance or nutritional status 
 Poor renal function 
 Liver dysfunction, especially elevated bilirubin 
 Cardiovascular disease 
 Comorbidity 
 HIV Infection 
 
Source: Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: 
American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 
2015;33(28):3199-3212.18 
 
 
2.6.2 Consensus & Guidelines Summary 
Despite slight differences in the guidelines, all the clinical practice guidelines 
developed by ASCO, NCCN and EORTC recommend the use of CSF for primary 
prophylaxis when the risk of febrile neutropenia is 20 percent or more in patients, and 
secondary prophylaxis if the patient previously had febrile neutropenia in a former cycle 
and chemotherapy dose reduction or delay will compromise care.108  
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The term ‘primary prophylaxis’ refers to when neutropenia is likely to occur in a 
patient after chemotherapy, but the patient has no prior experience. The term ‘secondary 
prophylaxis’ refers to when the patient had neutropenic fever (febrile neutropenia) in the 
past during a chemotherapy cycle and is expected to have it again. “Supportive uses” of 
CSF are efforts to reduce the duration of severe neutropenia in patients who are afebrile.  
2.7 ISSUES WITH CSF USE IN ONCOLOGY  
When CSFs are used appropriately, the risk of toxicities such as febrile neutropenia 
are reduced in patients. As discussed above, guidelines recommend the routine prophylaxis 
of CSFs starting from first cycle when the risk of febrile neutropenia is 20 percent or more. 
The issue with risk assessment is that risk of febrile neutropenia varies with chemotherapy 
regimens and other factors like disease, treatment and patient specific risk factors. The 
ASCO guidelines made a distinction between risk factors that increase the chances of 
neutropenia and risk factors that increase the risk of serious complication or morbidity in 
patients who develop febrile neutropenia, though some of these factors overlap.  
 Due to some issues that arise from assessing patient risk of febrile neutropenia, risk 
models have been developed and used to predict risk of neutropenia in patients receiving 
chemotherapy. However, model performances have been limited and have challenged its 
use. These models still require further validation and improvements, which some studies 
have attempted.110 An example can be found in Lyman et al. (2011) where a risk model for 
predicting complications from neutropenia was developed and validated in a population of 
cancer patients receiving chemotherapy via a prospective cohort study. The authors found 
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that patient risk of neutropenia was greatest in the first cycle of chemotherapy. The model 
performance was good, with 90 percent sensitivity, 59 percent specificity, positive 
predictive value of 34 percent and negative predictive value of 96 percent.111 A study that 
assessed the correlation between physician assessed and model predicted risk of febrile 
neutropenia in patients with non-myeloid tumors receiving found a weak correlation 0.249 
(95% C.I, 0.179 – 0.316).112  
2.8 FACTORS ASSOCIATED WITH CSF USE  
Studies have assessed the factors associated with CSF use among cancer patients 
receiving chemotherapy. Generally, factors found to be associated with clinical use of 
CSFs include physician, patient, clinical and facility factors. The physician factors include 
the physician’s compensation, knowledge and experience. Patient factors consist of race, 
comorbidities, geographic factors, patient beliefs and attitudes. Clinical factors include 
cancer type, disease severity and chemotherapy regimen. The facility factors include 
practice setting and healthcare setting.20  For example, a retrospective study assessed the 
factors associated with primary prophylaxis administration of CSF and variations of CSF 
administration among older patients with breast cancer using the SEER-Medicare database. 
The authors showed that significant geographical and racial disparities exist in CSF 
administration. In particular, a number of SEER regions, for instance California, were more 
likely to receive prophylactic CSF in comparison to other regions. Also, whites had a 
higher chance of receiving prophylactic CSF. They equally found that neutropenia risk 
associated with chemotherapy regimen is predominantly associated with CSF 
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administration.9 Another study assessed the use of CSF in a population based cohort of 
lung and colorectal cancer patients enrolled at Cancer Care Outcomes Research and 
Surveillance Consortium (CanCORS). The authors found intermediate risk regimen, severe 
comorbidity and non-HMO enrollment were strongly associated with CSF use. They also 
found that 96 percent of CSFs were used outside of ASCO and NCCN guidelines.21 
 A retrospective cohort study that analyzed CSF utilization in elderly cancer patients 
(breast, lung and non-Hodgkin lymphoma) using Medicare data found that chemotherapy 
cycle and risk associated with chemotherapy regimen are predictors of CSF 
administration.22 A study of CSF among breast cancer patients in a clinical practice setting 
showed that patients who had higher risk regimens were more likely to receive G-CSF 
primary prophylaxis and achieve relative dose intensity than those with lower risk 
regimens.12 In a study of early stage breast cancer patients from a single center, physician 
perceived risk of febrile neutropenia (FN) in patients largely influenced their decision to 
use CSF for primary prophylaxis.113 
2.9 ADHERENCE TO GUIDELINES  
CSFs have the potential to be overused and this has remained a problem for 
decades. Studies have shown that their use is inconsistent with clinical practice 
guidelines.21,114-118 This misuse is characterized by both underutilization and 
overutilization and has been linked to several factors as described above.20 Studies suggest 
that the non-adherence to clinical guidelines involves CSFs’ underutilization in high risk 
patients and overutilization in low risk patients.21,114,115 For instance, a survey of over 1200 
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ASCO physicians found that 28 percent of respondents used G-CSF prophylactically in 
patients at low risk for febrile neutropenia (<20%) ,while 48 percent used G-CSF as adjunct 
to antibiotics to treat febrile neutropenia.118 Krzemieniecki et al. assessed adherence to 
guidelines on primary prophylaxis with G-CSF use found that a significant portion (45 – 
80%) of all patients across tumor types did not receive the drug in accordance with 
recommendations. They also found that G-CSF was not administered within the 
recommended timeframe in patients.119 Another study assessed the effect of program 
guidance on prescribing attitudes of G-CSF agents and found a significant increase in use 
of filgrastim biosimilars and a decrease in use of lenograstim and pegfilgrastim post 
intervention.11 
2.10 CANCER CARE INITIATIVES  
Due to the high costs associated with cancer care, some initiatives have been 
launched that are aimed towards improving the quality of care and reducing costs. Some 
of these initiatives include the Choosing Wisely campaign and the Oncology Care Model 
(OCM).  
2.10.1 Choosing Wisely Campaign 
The Choosing Wisely campaign is a 2011 initiative of the American Board of 
Internal Medicine (ABIM) foundation. The aim of the campaign is to encourage clinician-
patient conversations and provide support to patients to choose care that is evidence-based, 
not repetitive, safe and really needed. Thus, providers and specialists choose wisely by 
identifying the commonly used tests and procedures in their field of practice whose need 
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should be questioned. This resulted in a list of recommendations by national organizations 
that represent medical specialists. The list intends to begin discussions about the relevance 
of many frequently ordered tests and treatments. The list does not intend to be used as 
landmark for coverage decisions or exclusions, but to encourage talks about appropriate 
and necessary treatments.  
 In addition, the campaign has patient-friendly materials to foster patient 
empowerment and engagement. There are communication education modules on the 
Choosing Wisely website [http://www.choosingwisely.org/] to aid providers in developing 
skills to communicate better with their patients. Furthermore, the ABIM foundation awards 
grants to support projects and initiatives by organizations that promote the goals of the 
Choosing Wisely campaign.120 
2.10.2 Oncology Care Model 
The oncology care model was launched by the Center for Medicare & Medicaid 
Innovation Center. OCM was established in order to develop and test “new payment and 
service delivery models” that incorporate value and quality in cancer care and promote care 
that is patient centered. One of the priorities of the OCM is to raise the value of care in 
oncology. The OCM employs performance-based payment incentives and “practice 
redesign activities” towards its goal of improving quality while reducing costs. The OCM 
model was implemented in 2016 and is expected to run until 2021.121  
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2.11 STUDY SIGNIFICANCE 
CSFs have been shown to be effective in the management of febrile neutropenia. 
Though CSFs reduce the incidence and severity of febrile neutropenia, their use for primary 
prophylaxis comes with significant cost implications which include direct drug acquisition 
costs and drug administration costs.113 A 2009 study estimated the cost of filgastrim and 
pegfilgastrim to be US$270 daily for up to 11 days and US$2100 per dose, respectively.122 
Besides, there are other healthcare costs (direct nonmedical costs and indirect costs) to 
consider. The costs for the routine use of these medications imposes a financial burden on 
the health system.113 The problem of associated costs and adverse events played a role in 
the development of guidelines for use of CSFs by major cancer societies, including ASCO 
as detailed above, in order to encourage proper use of medications based on evidence via 
clinical trials and other factors.18 
 The original clinical guidelines set the clinical threshold for CSF administration at 
40 percent risk of febrile neutropenia and the use of CSFs was justified based on economic 
reasons. But the current threshold puts CSF use at 20 percent risk of febrile neutropenia 
with the guidelines stating that CSF use should be due to clinical and not financial 
reasons.18,90 Due to CSFs being expensive yet important, several studies have carried out 
cost-effective analyses with varying results. A study that compared primary vs secondary 
prophylaxis found primary prophylaxis with filgastrim and pegfilgastrim not to be cost 
effective from the perspective of a publicly funded healthcare system.123 Besides, studies 
have shown that pegfilgastrim is the most cost-effective G-CSF, even though filgastrim is 
more commonly used. Other studies support the cost-effectiveness of pegfilgastrim 
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compared to filgastrim122,124 and lenograstim.124 Moreover, current G-CSF sales are 
estimated at Canadian $5.2 billion annually,123 therefore, reducing inappropriate usage of 
CSF could yield significant cost savings. 
The goal of this study was to describe the characteristics of CSF users as well as 
the prevalence and patterns of CSF use and dose reduction in a population-based cohort of 
metastatic colorectal cancer patients, to assess the factors associated with CSF use, dose 
reduction and mortality and to evaluate the compliance to ASCO practice guidelines on 
use of CSF. This study will help to pinpoint factors associated with inappropriate use of 
CSF utilization.  Targeting these factors could help decrease the inappropriate use of CSFs 
and may result in enhanced clinical practice, cost savings and improved outcomes.  
2.12 RESEARCH QUESTIONS 
 The specific research questions this study aims to answer include: In a population 
of metastatic colorectal cancer patients: 
 What are the characteristics of CSF users? 
 What is the prevalence of CSF use and dose reduction? 
 What are the patterns of CSF administration and dose reduction?  
 Is there a significant difference in CSF use pre- vs post-period?  
 Is there a significant difference in compliance rates pre- vs post-period?  
 What factors predict CSF use? 
 What factors predict dose reduction? 
 What factors predict all-cause mortality? 
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 What is the impact of CSF use vs dose reduction on all-cause mortality? 
Based on this literature review of past evidence, the general hypothesis is that a 
combination of patient, clinical, physician and geographical characteristics will influence 
CSF use in this population. Younger, white, sicker patients with a higher risk of febrile 
neutropenia and presence of comorbidities are more likely to use CSF than those who do 
not have these characteristics. Proposed models of the study that addresses these questions 
and hypotheses can be found in Figures 2.4 to 2.6.  
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Figure 2.4: Study Model: Predictors of CSF Use, Dose Reduction and Mortality  
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Figure 2.5: Study Model: Comparative Effectiveness of CSF Use vs Dose Reduction 
on Mortality 
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Figure 2.6: Study Model: Impact of Guidelines on CSF Use  
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CHAPTER 3: METHODOLOGY 
This study was designed to describe the use of CSF among metastatic colorectal 
cancer patients, to examine the impact of a program initiative on use of CSF, to evaluate 
the compliance of a multi-center oncology practice network to guidelines on CSF use, and 
to explore the factors associated with CSF use, chemotherapy dose reduction and mortality. 
This chapter outlines the research methodology that was used to conduct this study. The 
chapter is divided into nine major sections: study design, study objectives and hypotheses, 
study variables, the program initiative, data source and sample, ethical procedures, sample 
size determination, data analysis, and statistical assumptions. 
3.1 STUDY DESIGN 
This is a retrospective observational study. All data was obtained from the 
electronic health records of patients receiving care from a multi-center oncology practice 
network, which partnered with us to conduct this study. The impact of the program 
initiative on prescription patterns was evaluated using a pre- vs post- comparison.  
 3.2 STUDY OBJECTIVES AND HYPOTHESIS 
The specific objectives and hypothesis of this study were: 
Objective 1: To describe the characteristics of CSF users in a cohort of metastatic 
colorectal cancer patients.  
This is to determine the characteristics of all patients in the cohort who received at least 
one CSF medication during the study period.  
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Objective 2: To describe the prevalence and patterns of CSF use and chemotherapy dose 
reduction in a cohort of metastatic colorectal cancer patients.  
The frequency of CSF prescriptions was reported for each quarter of the study period. This 
also assessed the frequency of chemotherapy dose reduction as an alternative to CSF. 
Objective 3: To evaluate the impact of a program initiative on CSF use. 
This is a comparison of CSF use in the pre- and post-periods. 
H1: CSF use will be significantly lower post-initiative compared to the pre-initiative 
period. 
Objective 4: To evaluate the impact of a program initiative on compliance to guidelines. 
This objective assessed compliance to ASCO guidelines on CSF use in the pre- and post-
periods. .  
H2: Compliance to guidelines will be significantly higher post-initiative compared to the 
pre-initiative period. 
Objective 5: To determine the relationship between CSF use (dependent variable) and the 
variables age, FN risk and year of diagnosis, while controlling for covariates (gender, 
disease, line of therapy and duration of treatment). 
H3a: Age is negatively associated with CSF use after adjusting for covariates. Younger 
subjects are more likely to receive CSF compared to older subjects. 
H3b: FN risk is positively associated with CSF use after adjusting for covariates. Subjects 
with higher FN risk will be more likely to use CSF compared to subjects with lower FN 
risk. 
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H3c: Year of diagnosis is positively associated with CSF use after adjusting for covariates. 
Subjects diagnosed in recent years are more likely to use CSF compared to subjects 
diagnosed in older years. 
Objective 6: To determine the relationship between dose reduction (dependent variable) 
and the variables age and FN risk. while controlling for covariates (gender, disease, line of 
therapy, year of diagnosis and duration of treatment). 
H4a: Age is positively associated with dose reduction after adjusting for covariates. Older 
subjects are more likely to receive dose reduction compared to younger subjects. 
H4b: FN risk is positively associated with dose reduction after adjusting for covariates. 
Subjects with higher FN risk will be more likely to receive dose reduction compared to 
subjects with lower FN risk. 
Objective 7: To determine the relationship between all-cause mortality (dependent 
variable) and the variables age, CSF use and dose reduction, while controlling for 
covariates (FN risk, gender, disease, line of therapy, year of diagnosis and duration of 
treatment). 
H5a: Age is positively associated with mortality after adjusting for covariates. Older 
subjects will have higher odds of death compared to younger subjects. 
H5b: CSF use is negatively associated with mortality after adjusting for covariates. 
Subjects who received CSF will have lower odds of death compared to subjects who did 
not receive CSF. 
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H5c: Dose reduction is negatively associated with mortality after adjusting for covariates. 
Subjects who received dose reduction will have lower odds of death than those who did 
not receive dose reduction. 
Objective 8: To compare the effect of dose reduction to the effect of CSF use on all-cause 
mortality in the population. 
H6: The variable ‘compare’ (CSF Use vs Dose Reduction) is not significantly associated 
with mortality after adjusting for covariates. There will be no difference in odds of death 
between subjects who received CSF and subjects who received dose reduction.  
3.3 STUDY VARIABLES 
The study variables include demographic, clinical and therapeutic characteristics. A 
description of all variables is detailed below, and their operational definitions can be found 
in Table 3.1. 
3.3.1 Dependent Variables 
Primary Dependent Variable 
CSF Use: CSF use is defined as the use of the CSF medication pegfilgrastim (Neulasta), 
during the study time period. The variable was grouped into two categories: 0 for no CSF 
use, 1 for CSF use.  
 
Secondary Dependent Variables 
Dose Reduction: This occurs when a patient’s chemotherapy dose is reduced and is defined 
a10% reduction in chemotherapy dose compared to standard dose at first dosing, or patient 
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receiving a second dose that is 10% lower than first dose. This had two categories: 1=Dose 
Reduction 0=No dose reduction 
Death (Mortality): Death of patient. This had two categories: 0= No 1=Yes.  
3.3.2 Predictor Variables 
The predictor variables are grouped into demographic factors, clinical factors, and 
therapeutic factors. 
Demographic variables 
Age: patient age at chemotherapy. There was both a continuous and categorical age 
variable. The categorical age variable was categorized into four groups : <60, 60-70, 70-
80, and >80. 
Gender: patient gender had two categories : 0 = male, 1 = female. 
Clinical variables 
Disease:  specifies if the patient had colon or rectal cancer and was categorized namely: 0 
= rectal cancer, 1 = colon cancer 
Year of Diagnosis: refers to the year the patient was diagnosed and was coded into three 
categories: 0=1988-2007, 1= 2008-2012 and 2=2013-2017.  
 
 
Therapeutic variables 
FN Risk: patient’s risk of febrile neutropenia. This was determined from the chemotherapy 
regimen of the patient. This risk is usually determined by the physician and is associated 
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with the chemotherapy regimen administered, as well as other disease, treatment or patient 
specific factors. In order to assign FN risk, the chemotherapy regimen was identified from 
the data, then patients were grouped into categories based on the risk of the chemotherapy 
regimen. The categories are: 0 = low risk, 1= intermediate risk. The regimen to risk 
assessment was based on the NCCN guidelines. The chemotherapy risk categorizations 
used for this can be found in Table 3.2. 
Line of Therapy: refers to the line of treatment the patient received and was categorized as 
0 = first line, 1 = second line, 2 = third line and 3 = beyond 3rd line.  
Duration of Treatment: refers to the length of time from start to end of chemotherapy and 
was recoded into three categories: 0= 0-12 months, 1= 13-23 months and 2= 24 and above 
months.  
3.3.3 Other Descriptor Variables 
Other descriptor variables include those that were required to calculate and operationally 
define other variables, and to describe the population. 
Chemotherapy regimen: chemotherapy agent administered to the patient. This is a specific 
drug or drug combination administered and was used to determine the FN risk.  
Number of CSF administrations: refers to the number of CSF administrations a patient 
received. This was used to better describe the population.  
Compare: isa variable with two levels created to compare two categories of subjects, 0 = 
dose reduction and 1= CSF use 
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Compliance: refers to whether there was compliance to ASCO guidelines on CSF use for 
each patient and was determined from patient data. ASCO recommends CSF 
administration for patients with a high risk of FN. CSF use is not recommended for low 
and intermediate risk patients. A patient was compliant if they received CSF given that 
they have a high-risk regimen, or if they did not receive CSF and were at low or 
intermediate risk. 
3.4 THE PROGRAM INITIATIVE  
The Choosing Wisely campaign was developed and implemented to address the 
overuse of some tests and treatments in clinical practice with a general aim of avoiding 
unnecessary or wasteful use of resources. The tests and treatments of concern span across 
all areas of medical practice such as oncology, cardiology, and emergency medicine, and 
examples of each include the recommendations against: routine use of breast MRI for 
breast cancer screening in average risk women, routine electrocardiography screening for 
asymptomatic patients with myocardial infarction and routine CT scanning of children with 
mild head injuries, respectively.  Choosing Wisely was launched in 2012 by the ABIM 
Foundation and currently consists of over a million clinicians from over 70 societies as 
partners.125 
Beginning March 2016, the multicenter oncology network which partnered with us 
for this study incorporated a program improvement initiative into their clinical practice 
with an aim of improving appropriate use of CSFs and compliance to ASCO guideline 
recommendations. Educational materials were sent to all physicians. The evidence-based 
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recommendations on CSF use were communicated to physicians and a cost-effective 
approach was recommended for the physicians. By 2017, prior authorization was required 
for CSF prescription, and CSF use was tracked via electronic health records.  
As detailed earlier, ASCO recommends that (1) CSFs be used as primary 
prophylaxis starting from first chemotherapy cycle when risk of febrile neutropenia is 20 
percent or higher. However, alternative, equally effective, and safe chemotherapy regimens 
not requiring CSF support should be given when available. (2) CSFs should be used as 
secondary prophylaxis for patients who already had neutropenia from a prior cycle. 
However, dose reduction or delay is also a reasonable alternative and (3) CSFs should not 
be used as adjunctive treatment with antibiotics in patients with febrile neutropenia.  
 In this study, compliance was defined as a patient receiving CSF if at high risk, or 
not receiving CSF if not at high risk.  
 
 
 
 
Table 3.1: Study Variables and Operational Definitions 
Variable Operational Definition Categories 
Dependent   
CSF Use Use of pegfilgrastim (Neulasta) 
during study time period.  
 
0 = patient did not 
receive CSF 
1 = patient received CSF 
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Table 3.1: Study Variables and Operational Definitions (Cont’d) 
Secondary Dependent 
Dose Reduction  Up to 10 percent reduction in dose of 
chemotherapy compared to standard 
dose 
0 = No 
1 = Yes 
Death (Mortality) Mortality status of patient 0= No 
1= Yes 
Independent   
Demographic Factors   
Age Age at chemotherapy (years) 0= <60 years 
1= 60 – 69 years 
2= 70 – 79 years 
3= 80 and above years 
Gender Patient gender 0= male 
1= female 
Clinical Factors   
Disease Colon or rectal cancer 0= rectal cancer 
1= colon cancer 
Year of Diagnosis Year patient was diagnosed 0 = 1988- 2007 
1= 2008- 2012 
2= 2013- 2017 
Therapeutic Factors   
FN Risk Patient’s risk of febrile neutropenia 
(was determined from chemotherapy 
regimen using NCCN guidelines) 
 
0= Low risk 
1= Intermediate risk 
 
Line of Therapy The line of treatment patient received 0= first line 
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1= second line 
2= third line 
3= beyond the third line 
Duration of Treatment  0= 0 – 12 months 
1= 13- 23 months 
2= 24 and above months 
Other descriptor Variables   
These variables are required to calculate and operationally define outcome variables. 
Chemotherapy regimen Chemotherapy agent or combination 
of agents administered to the 
patients. This will be used to assign 
FN risk. 
 
No. of CSF Administrations Number of CSF administrations a 
patient received 
0 = 0 administrations 
1= 1-10 administrations 
2= 11-20 
administrations 
3= >20 administrations 
Compare A variable with two levels 0= dose reduction 
1= CSF Use 
Compliance Compliance to ASCO 
recommendations on use of CSF. 
Compliant: patient received CSF if 
they have a high-risk regimen, or did 
not receive CSF if they have a low or 
intermediate risk regimen 
Non-compliant: patient received CSF 
but was at low or intermediate risk 
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Table 3.2: Chemotherapy Regimen Risk Categorizations 
Agent/Combination of Agents Regimen Name FN Risk 
Irinotecan, leucovorin, fluorouracil FOLFIRI Low 
FOLFIRI+ bevacizumab  Low 
Fluorouracil 5-FU Low 
Panitumumab Panit Low 
Irinotecan IRIN Low 
Bevacizumab BEVACIZ Low 
Cetuximab CETUX Low 
Capeox  Low 
Oxaliplatin  Low 
Fluorouracil, Bevacizumab, Irinotecan, 
Leucovorin, Capecitabin 
5-FU|Bevaciz|Irin|LV|XELO Low 
Fluorouracil, Bevacizumab 
Leucovorin 
5-FU|Bevaciz|LV Low 
Fluorouracil, Irinotecan Leucovorin, 
Panitumumab 
5-FU|Irin|LV|Panit Low 
Fluorouracil, Irinotecan, Ziv-
Aflibercept 
5-FU|Irin|Ziv-Aflib Low 
Fluorouracil, Leucovorin, Oxaliplatin, 
Panitumumab 
5-FU|LV|Oxali|Panit Low 
Fluorouracil, Bevacizumab  5-FU|Bevaciz Low 
Fluorouracil, Cetuximab, Irinotecan, 
Leucovorin,  
5-FU|Cetux|Irin|LV Low 
Fluorouracil, Leucovorin calcium, 
Oxaliplatin 
FOLFOX Intermediate 
Fluorouracil, Leucovorin calcium, 
Oxaliplatin, Bevacizumab 
FOLFOX + Bev Intermediate 
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Table 3.2: Chemotherapy Regimen Risk Categorizations (Cont’d) 
Fluorouracil, Irinotecan hydrochloride, 
Leucovorin, and Oxaliplatin 
FOLFIRINOX Intermediate 
Fluorouracil, Irinotecan, Leucovorin, 
Oxaliplatin, Bevacizumab 
FOLFIRINOX + Bev Intermediate 
Fluorouracil, Leucovorin, Oxaliplatin, 
Panitumumab 
5-FU|LV|Oxali|Panit Intermediate 
Fluorouracil, Bevacizumab, Irinotecan, 
Oxaliplatin 
5-FU|Bevaciz|Irin|Oxali Intermediate 
Cisplatin, Etoposide CIS|ETOP Intermediate 
Fluorouracil, Bevacizumab, 
Leucovorin, Oxaliplatin, Capecitabin 
5-FU|Bevaciz|LV|Oxali|Xelo Intermediate 
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3.5 DATA SOURCE AND SAMPLE 
3.5.1 Data Source 
The data used for this study were obtained from the electronic health records of 
colon and rectal cancer patients enrolled in a multi-center oncology practice. This multi-
center oncology practice is an individual network of over 400 physicians and oncology 
specialists. The practice delivers advanced treatment options and high touch care to cancer 
patients and spans across three states. It was founded in 1986 and has grown to have over 
100 offices in Texas, New Mexico and Oklahoma. The database captures data from more 
than 175 sites of service in its network and contains patient demographics, disease 
characteristics and all billed services of enrolled patients.  
3.5.2 Sample and Eligibility 
The sample used for this study was made up of metastatic colorectal cancer patients 
receiving care at all sites of the oncology practice network. The criteria used in sample 
selection and eligibility are as follows: 
Inclusion Criteria 
Diagnosed with colon or rectal cancer 
Currently in metastatic stage (i.e., stage 4) 
Received chemotherapy 
Exclusion Criteria 
Colorectal cancer patients in stages 0 to 3 
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3.6 ETHICAL PROCEDURES 
The study was carried out according to the human subjects’ research guidelines of 
The University of Texas Institutional Review Board (IRB). An IRB application was 
submitted for this study and the protocol was approved. Also, the data were obtained and 
analyzed in de-identified form to protect patient privacy.  
3.7 SAMPLE SIZE DETERMINATION 
Power analysis was conducted a priori using the G power 3.1.9.2 software. This 
was necessary in order to determine the minimum sample size required for each analysis 
in the study. For a priori calculation, the required sample size of a study (N) is based on 
three parameters: the required power level, the prespecified significance level, and the 
population effect size.126 Sample size was determined for all possible analyses in this study. 
It was based on a power of 0.80, an alpha of 0.05 and conventional medium effect sizes. 
Using a medium effect size of 0.5, the results gave a minimum total sample size 
requirement of 128 (64 in each group) for a t test analysis. One rule of thumb for logistic 
regression sample size, is to use 10 – 20 subjects per independent variable,127 which results 
in a required sample size of 80 – 120 for this study. The minimum total sample size 
requirement for a t-test and chi-square analyses (two tailed) using conventional effect 
sizes128 can be found in Table 3.3.  
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Table 3.3: Power Analysis 
Analysis Power alpha Effect size Sample size 
T – test 0.80 0.05 0.50 128 
Chi-square 
goodness of fit 
0.80 0.05 0.30 143 
 
3.8 DATA ANALYSIS 
All data for this study were analyzed using SAS version 9.4 (SAS Institute, Cary, 
N.C). The a priori base alpha level was set at 0.05. The pre- and post- initiative periods 
were defined as July 1, 2013 to December 31, 2014 and July 1, 2017 to December 31, 2017, 
respectively. The program initiative was implemented starting March 2016, up till 2017.  
 
Figure 3.1 Data Extraction and Subject Identification Period 
 
 
 
 
 
 
July 2013                      Dec 2014    Mar2016- Mar2017       July 2017                     Dec 2017 
 
      Pre-initiative period                                                Post- initiative period 
                                                         Initiative Period 
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Descriptive Statistics:  
 Descriptive statistics (means, standard deviations, frequencies and percentages) 
were performed on all study variables to determine the baseline characteristics of the 
sample and to determine the prevalence and patterns of CSF use and dose reduction. Means 
and standard deviations were used to describe the continuous age variable while frequency 
and percentages were used to describe gender, the categorized age variable, type of disease, 
year of diagnosis, line of therapy, duration of therapy, FN risk and the categorized number 
of CSF administrations.   
Chi-squared analyses: 
Chi squared tests were used to determine the difference in patient characteristics 
between the pre and post groups and between CSF users and non-users. Chi squared tests 
were used for categorical variables. Fishers exact test was used for variables whose 
contingency table cells had expected counts less than 5.  
T-test analyses:  
 T tests were conducted to determine the difference in patient characteristics 
between the pre and post groups and between CSF users and non-users. T tests were used 
for continuous variables. 
Logistic Regression:  
 Logistic regression models were used to explore the factors associated with CSF 
use, factors associated with dose reduction and factors associated with mortality in the 
population. These models determined the predictive ability of each of the predictor 
variables, while controlling for covariates. The model is as follows: 
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Logit [(Y)] = log (π/1-π) = b0 + b1X1 + b2X2 + b3X3 + b4X4 + b5X5 + b6X6 + b7X7 + 
ei, where 
π = probability of success (CSF Use = 1) 
1 – π = probability of failure (CSF Use = 0) 
Y1= CSF Use 
Y2= Dose Reduction 
Y3= Mortality 
b0= intercept 
X1= age 
X2= FN risk 
X3= year of diagnosis 
X4= gender 
X5= disease 
X6= line of therapy 
X7= duration of treatment 
ei=   error term 
Y is the dependent variable CSF use for the first model, dose reduction for the second 
model, and mortality for the third model. The Bs are the regression coefficients of the 
independent variables. The logistic regression analyses were conducted in two steps. First, 
a univariate model was run independently for the dependent variable and each covariate 
and results reported in a table as unadjusted analyses. Then, the significant variables at the 
5 percent significance level were included for the multivariate models. This was to create 
more parsimonious final models.  
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3.9 STATISTICAL ASSUMPTIONS 
T-Test Assumptions 
 The t test assumptions of linearity, normality, independence and homoscedasticity 
were assessed before running the analyses.129  To assess the normal assumption, the 
peakness and symmetry of the distribution were determined using skewness and kurtosis. 
Scatterplots were used to assess the linearity assumption while residual vs fitted plots were 
used to assess the constant variance assumption. 
Chi-square Assumptions 
 The chi square assumptions of independence and expected cell count were assessed 
prior to running the analyses. The assumption of independence means that the data should 
not be correlated or matched pairs. If the two groups are related, then a different test must 
be used. The value of the expected cell counts should be five or more and each cell should 
have a count of one or greater. Also, the data in the cells should be counts, not percentages 
or transformations of the data.130 For instances where the assumptions were not met, a 
fishers exact test was used. 
Logistic Regression Assumptions 
 The assumptions of a logistic regression analysis were likewise assessed before 
running the analyses. The assumptions include independence of errors, linearity in logit, 
absence of multicollinearity and absence of strong outliers. The independence of errors 
assumes that the observations in the data are independent and there are no duplicate 
responses. This was met by the data in this study, as there are no repeated measures or 
duplicate outcomes. The linearity in logit assumption assumes a linear relationship between 
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the continuous independent variables and their log odds (i.e., its logit transformed 
outcomes).127 
 The assumption of absence of multicollinearity means that the independent 
variables are not redundant or correlated with each other. A violation of this assumption 
could lead to large standard errors for the slopes of the variables and can decrease statistical 
power. This was addressed by eliminating the redundant variables from the model. 
Multicollinearity in this study was checked by calculating the variance inflation factor 
(VIF) and spearman correlations of independent variables. Multicollinearity was said to 
exist when the VIF was greater than 10131 or tolerance was less than 0.1.  
 Another assumption is the absence of strong outliers. The presence of strong 
outliers could compromise the accuracy of the models. Outliers were checked via a visual 
inspection of residuals in the diagnostic graphs.127 Logistic regression also requires an 
adequate sample size. The rule of thumb is to use 10 – 20 events per independent variable, 
which gives a required minimum sample size of 80 for this study so the large sample size 
assumption was met.  
 Table 3.4 contains all the study variables and their measurement levels, while Table 
3.5 contains a summary of study objectives, hypotheses and corresponding statistical tests.  
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Table 3.4: Study Variables and Measurement Levels 
Study Variable Measurement Level 
Dependent Variables  
CSF Use Nominal 
Compliance Nominal 
Dose Reduction Nominal 
Independent Variables  
Age Interval & Nominal 
Gender Nominal 
Febrile Neutropenia Risk Nominal 
Disease Nominal 
Year of Diagnosis Nominal 
Line of Therapy Nominal 
Duration of Treatment Nominal 
Other Descriptor Variables  
Chemotherapy Regimen Nominal 
Number of CSF Administrations Nominal 
Compare Nominal 
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Table 3.5: Study Objectives, Hypotheses and Corresponding Statistical Tests 
Objectives/Hypotheses Dependent 
Variables 
Independent 
Variables 
Statistical 
Tests 
Objective1: To describe the characteristics of CSF users in a cohort of metastatic colorectal cancer 
patients 
 
Objective2: To describe the prevalence and patterns of CSF use and dose reduction in a cohort of 
metastatic colorectal cancer patients 
Objective 3: To evaluate the impact of a program initiative on CSF prescription prevalence 
H1: CSF use will be significantly 
lower post-initiative compared to the 
pre-initiative period 
CSF Use  t-test and 
Chi-squared 
test 
Objective 4: To evaluate the impact of a program initiative on compliance to guidelines  
H2: Compliance to guidelines will be 
significantly higher post-initiative 
compared to the pre-initiative period. 
CSF Use  Chi-sqaured 
test 
Objective 5: To determine the relationship between CSF use (dependent variable) and the variables 
age, FN risk, and year of diagnosis, while controlling for covariates 
 
H3a: There is a significant and 
negative relationship between age 
and CSF use while controlling for 
covariates. 
 
CSF Use  
Predictors 
 Age 
 FN Risk 
 Year of 
Diagnosis 
 
 
Covariates 
 Gender 
 Disease 
 Line of 
Therapy 
 Duration of 
treatment 
Logistic 
Regression 
H3b: There is a significant and 
positive relationship between FN risk 
and CSF use while controlling for 
covariates. 
 
CSF Use 
H3c: There is a significant and 
positive relationship between year of 
diagnosis and CSF use while 
controlling for covariates. 
 
CSF Use 
Objective 6: To determine the relationship between dose reduction (dependent variable) and the 
variables age and FN Risk while controlling for covariates 
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Table 3.5: Study Objectives, Hypotheses and Corresponding Statistical Tests (Cont’d) 
H4a: Age is significantly and 
positively associated with dose 
reduction after adjusting for 
covariates 
 
Dose Reduction Predictors 
 Age 
 FN Risk 
 
 
Covariates 
 Gender 
 Disease 
 Line of 
Therapy 
 Duration of 
treatment 
 
Logistic 
Regression 
H4b: FN risk is significantly and 
positively associated with dose 
reduction after adjusting for 
covariates 
 
Dose Reduction 
Objective 7: To determine the relationship between all-cause mortality (dependent variable) and the 
variables age, CSF use and dose reduction, while controlling for covariates 
 
 
H5a: Age is significantly and 
positively associated with mortality 
after adjusting for covariates. 
Mortality Predictors 
 Age 
 CSF Use 
 Dose 
Reduction 
 
Covariates 
 Gender 
 Disease 
 Line of 
Therapy 
 Duration of 
treatment 
 
Logistic 
Regression 
H5b: CSF use is significantly and 
negatively associated with mortality 
after adjusting for covariates. 
Mortality 
H5c: Dose reduction is significantly 
and negatively associated with 
mortality after adjusting for 
covariates. 
Mortality 
Objective 8: To compare the effect of  CSF use to the effect of dose reduction on all-cause mortality 
in the population 
H6: The variable ‘compare’ (CSF 
Use vs Dose Reduction) is not 
significantly associated with 
mortality after adjusting for 
covariates. 
Mortality Predictor 
 A variable 
‘compare’ 
with two 
levels: CSF 
Use and 
Dose 
Reduction 
 
Covariates 
Logistic 
Regression 
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 Gender 
 Disease 
 Line of 
Therapy 
 Duration of 
treatment 
 Age 
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CHAPTER 4: RESULTS 
The findings of this study are presented in this chapter. The first section describes 
the data pooling and preliminary analysis. The second section describes the demographics 
of the study population. The other sections present the statistical analyses, and 
corresponding results and tables, which are organized by the study objectives. Data were 
collected at two different time periods (pre-period and post-period). For objectives that 
involved a pre- vs post- comparison, the entire data set was used. For objectives that did 
not involve a pre- vs post- comparison, only the pre-period data were used.  
4.1 DATA PREPARATION AND CLEANING 
 The data used in this study were obtained from electronic health records of patients 
in a multi-center oncology practice network. Data were pooled at the regimen level for 
subjects who met the selection criteria for the two time periods used in this study. The pre-
period was defined as 7/1/2013 to 12/31/2014, while the post-period was defined as 
7/1/2017 to 12/31/2017. The pre-period had 2541 regimens (observations) corresponding 
to 2131 unique patients, while the post-period had 885 regimens (observations), 
corresponding to 837 unique patients. The full data set consisted of a total number of 3426 
regimens, corresponding to 2968 unique patients.  
4.2 PRELIMINARY ANALYSIS 
Data were assessed for normality and missingness. To assess normality, the 
distribution of all interval level variables had to fall within the threshold of |2| and |7|, 
respectively. The histograms and Q-Q plots were visually inspected as well [see Appendix 
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A]. The variables number of CSF administrations and duration of treatment did not meet 
the normality threshold and were categorized [See Table 4.1]. Although age was normally 
distributed, it was categorized as well to determine if statistical differences exist based on 
the different age groups. Missingness was observed in the variables gender (0.03%), 
duration of treatment (0.03%), FN risk (2.8%) and dose reduction (80.0%). Dose reduction 
was only available in the pre-period data and had 80% missingness. The observed 
missingness was not at random but systematic, because the dose reduction variable was 
only available for patients who had a baseline oncology care model (ocm) episode. Due to 
this, data imputation technique could not be used. Therefore, all analyses that required the 
dose reduction variable were conducted using the pre-period cohort, and the missingness 
limits the study.  
Table 4.1: Skewness and Kurtosis of Interval Level Variables 
Variable Skewness Kurtosis 
Age (years) -0.2503 -0.1531 
CSF Administrations 60.7044* 60.1559* 
Duration of treatment 
(months) 
2.3285* 7.5996* 
*skewed 
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4.3 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS  
The baseline characteristics of the subjects are described in this section. The 
characteristics were described for the entire study population, as well as for each cohort.  
There was a total of 3426 regimens. The  average age of the population was 61.8 
±12.0 years (median=62.0, mode=59.0), with a range of 19.0 to 89.0 years. The mean 
duration of treatment was 6.8 months. A majority of the subjects were male (59.4%),  more 
than 60 years of age (58.2%), had colon cancer (74%) and were diagnosed between 2013 
and 2017 (65.3%). For the therapeutic characteristics, most of the subjects had low FN risk 
(56.3%), were treated within a year (87.1%) and were lost to death (54.2%) at the time data 
were collected. Chi square and fishers’ exact tests showed statistically significant 
differences between the pre- and post- period groups for the variables’ year of diagnosis, 
duration of treatment, CSF administrations and death.  
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Table 4.2: Characteristics of Study Participants  
Variable Frequency 
(%) 
Mean (SD) 
Age at chemotherapy  61.79 (11.99) 
Duration of treatment (months)   6.76 (6.95) 
Number of Subjects (n=3426) 
Pre – period 2541  
Post – period 885  
 Study group P value 
Pre-period 
(%) 
Post-period 
(%) 
Gender (n=3425)a   
Female 1392 (40.6) 1044 (41.1) 348 (39.4) 
0.3699 
Male 2033 (59.4) 1497 (58.9) 536 (60.6) 
Age group (n=3426)     
<60 years 1443 (41.8) 1040 (40.9) 393 (44.4)  
 
0.1487 
60 – 69 years 1063 (31.0) 789 (31.1) 274 (31.0) 
70 – 79 years 701 (20.5) 532 (20.9) 169 (19.1) 
80 and above years 229 (6.7) 180 (7.1) 49 (5.5) 
Year of Diagnosis (n=3426)     
88 – 07 126 (3.7) 116 (4.6) 10 (1.1) <0.0001* 
08 – 12 1061 (31.0) 1006 (39.6) 55 (6.2) 
13 – 17 2239 (65.3) 1419 (55.8) 820 (92.7)  
Disease (n=3426)   
Colon cancer 2543 (74.0) 1862 (73.3) 672 (76.0) 0.1213 
 Rectal cancer 892 (26.0) 679 (26.7) 213 (24.0) 
Line of therapy (n=3426) 
1st line 2015 (58.8) 1462 (57.5)  553 (62.5)  
 2nd line 1023 (29.9) 770 (30.3)  253 (28.6) 
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3rd line  307 (9.0) 240 (9.5)  67 (7.6)  
0.0113* Beyond 3rd 81 (2.4) 69 (2.8) 12 (1.4) 
FN Risk (n=3331)a   
Low 1876 (56.3) 1405 (56.7) 471 (55.2)  
0.43 Intermediate  1455 (43.7) 1072 (43.3) 383 (44.9) 
Duration of Treatment (n =3426)   
 0 – 12 months 2985 (87.1) 2150 (84.6) 835 (94.4)  
<0.0001* 13 – 23 months 331 (9.7) 281 (11.1) 50 (5.6) 
24+ months 110 (3.2) 110 (4.3) 0 (0.0) 
No. of CSF Administrations (n=3426) 
0 administrations 3039 (88.7) 2197 (86.5) 842 (95.1)  
 
<0.0001* 
1 – 10 administrations 296 (8.6) 261 (10.3) 35 (4.0) 
11 – 20 administrations 63 (1.8) 55 (2.2) 8 (0.9) 
>20 administrations 28 (0.9) 28 (1.1) 0 (0.0) 
Death (n=3426)     
Yes 1857 (54.2) 1606 (63.2) 251 (28.4)  
<0.0001* No 1569 (45.8) 935 (36.8) 634 (71.6) 
*significant at 0.05 
atotals do not equal 3426 due to missing responses 
 
4.4 OBJECTIVE 1: DESCRIPTION OF CSF USERS 
The first objective was to describe the demographic, clinical and therapeutic 
characteristics of CSF users in the population. Here, CSF use was defined as distinct CSF 
users (subjects who received CSF and did not receive dose reduction). The characteristics 
for the entire cohort and then for each time period (i.e., pre and post-period) are presented. 
The results are tabulated by CSF use. [See Tables 4.3 and 4.4]. 
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There were 343 CSF users in the entire cohort. The mean age of subjects who used 
CSF was 59.6 ±11.0  years. A majority of subjects who received CSF were female (47.5%) 
and were less than 60 years old (50.4%).  Most CSF users had colon disease (70.5%), were 
diagnosed between 2013 and 2017 (61.5%), had an intermediate FN risk (54.7%), received 
the first line of chemotherapy (61.5%) and were treated for a year or less (81.3%). 
Furthermore, 54.2% of CSF users were lost to death. The chi square test results comparing 
the two groups (CSF users vs non-users) showed a significant difference for the variables 
gender, age, line of therapy, FN risk and duration of treatment. Compared to non-users, 
CSF users had a significantly lower age, were significantly more likely to be female and 
have an intermediate FN risk. 
Table 4.3: Characteristics of CSF Users and Non-users 
Characteristica CSF Use No CSF Use Total  P-value 
Age, Mean (SD)  59.6 (11.0) 61.9 (12.1) 61.8 (12.0) 0.0002* 
Gender, n (%)     
Female 163 (47.5) 1205 (39.7) 1368 (40.6) 0.0049* 
Male 180 (52.5) 1833 (60.3) 2013 (59.4) 
Totalb 343 (100.0) 3038 (100.0) 3381(100.0)  
Age Group, n (%)     
<60  173 (50.4) 1267 (41.4) 1430 (42.3)  
0.0025* 60 – 69 104 (30.3) 943 (31.0) 1047 (30.9) 
70 – 79 51 (14.9) 626 (20.6) 677 (20.0) 
80 and above 15 (4.4) 213 (7.0) 226 (6.7) 
Total 343 (100.0) 3039 (100.0) 3382 (100.0)  
Disease, n (%)     
Colon  242 (70.5) 2260 (74.4) 2502 (74.0) 0.1271 
Rectal 101 (29.5) 779 (25.6) 880 (26.0) 
Total 343 (100.0) 3039 (100.0) 3382 (100.0)  
Line of Therapy,  
n (%) 
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Table 4.3: Characteristics of CSF Users and Non-users (Cont’d) 
1st line 211 (61.5) 1772 (58.3) 1983 (58.6)  
0.0087 2nd line 110 (32.1) 901 (29.7) 1011 (29.9) 
3rd line 14 (4.1) 293 (9.6) 307 (9.1) 
Beyond 3rd  8 (2.3) 73 (2.4) 81 (2.4) 
Total 343 (100.0) 3039 (100.0) 3382 (100.0)  
FN Risk, n (%)     
Low  149 (45.3) 1707 (57.7) 1856 (56.5) <0.0001* 
Intermediate 180 (54.7) 1251 (42.3) 1431 (43.5) 
Totalb 329 (100.0) 2958 (100.0) 3287 (100.0)  
Duration of 
Treatment, n (%) 
    
0 – 12 months 279 (81.3) 2674 (88.0) 2953 (87.3)  
0.0013* 13 – 23 months 51 (14.9) 273 (9.0) 324 (9.6) 
24+ months 13 (3.8) 92 (3.0) 105 (3.1) 
Total 343 (100.0) 3039 (100.0) 3382 (100.0)  
Year of Diagnosis, 
 n (%) 
    
88 – 07 11 (3.2) 114 (3.8) 125 (3.7)  
0.1619 08 – 12 121 (35.3) 921 (30.3) 1042 (30.8) 
13 – 17 211 (61.5) 2004 (65.9) 2215 (65.5) 
Total 343 (100.0) 3039 (100.0) 3382 (100.0)  
Death, n (%)     
Yes 186 (54.2) 1639 (53.9) 1825 (54.0) 0.9172 
No 157 (45.8) 1400 (46.1) 1557 (46.0) 
Total 343 (100.0) 3039 (100.0) 3382 (100.0)  
acolumn percentages presented, *significant at 0.05 
btotals do not equal 3426 due to missing responses 
 
4.4.1 Pre vs Post-period Characteristics and Comparisons  
Data for this study was obtained from two different time periods. For comparisons, 
Table 4.4 shows the characteristics of CSF users for both time periods distinctively. The 
number of patients who received CSF in the pre-period was higher than the number of 
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patients who received CSF in the post-period. In the post-period, there was no significant 
difference between CSF users and non-CSF users for any of the variables. 
Table 4.4: Characteristics of CSF Users and Non-users at Pre- and Post- Periods 
 Pre-period Post-Period 
Characteristicb CSF Use No CSF Use P-value CSF Use No CSF Use P-value 
Age, Mean (SD)  59.9 (11.0) 62.3 (12.07) 0.0004* 57.3 (11.2) 60.9 (12.1) 0.0555 
Gender, n (%)       
Female 142 (47.3) 878 (40.0) 0.0149* 21 (48.8) 327 (38.9) 0.1925 
Male 158 (52.7) 1319 (60.0) 22 (51.2) 514 (61.1) 
Totalc 300 (100.0) 2197 (100.0)  43 (100.0) 841 (100.0)  
Age Group, n (%)       
<60  148 (49.3) 889 (40.5) 0.0039* 25 (58.1) 368 (43.7) 0.2821 
 60 – 69 94 (31.3) 679 (30.9) 10 (23.3) 264 (31.4) 
70 – 79 44 (14.7) 464 (21.1) 7 (16.3) 162 (19.2) 
80 and above 14 (4.7) 165 (7.5) 1 (2.3) 48 (5.7) 
Total 300 (100.0) 2197 (100.0)  43 (100.0) 842 (100.0)  
Disease, n (%)       
Colon  208 (69.3) 1622 (73.8) 0.0989 34 (79.1) 638 (75.8) 0.6217 
Rectal 92 (30.7) 575 (26.2) 9 (20.9) 204 (24.3) 
Total 300 (100.0) 2197 (100.0)  43 (100.0) 842 (100.0)  
Line of Therapy, n 
(%) 
      
1st line 180 (60.0) 1250 (56.9) 0.0045* 31 (72.1) 522 (62.0) 0.3766a 
2nd line 101 (33.7) 657 (29.9) 9 (20.9) 244 (29.0) 
3rd line 12 (4.0) 228 (10.4) 2 (4.7) 65 (7.7) 
Beyond 3rd  7 (2.3) 62 (2.8) 1 (2.3) 11 (1.3) 
Total 300 (100.0) 2197 (100.0)  43 (100.0) 842 (100.0)  
FN Risk, n (%)       
Low  131 (45.8) 1254 (58.4) <0.0001* 18 (41.9) 453 (55.9) 0.0721 
Intermediate 155 (54.2) 893 (41.6) 25 (58.1) 358 (44.1) 
Totalc 286 (100.0) 2147 (100.0)  43 (100.0) 811 (100.0)  
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Table 4.4: Characteristics of CSF Users and Non-users at Pre- and Post- Periods (Cont’d) 
Duration of 
Treatment 
      
0 – 12 months 239 (79.7) 1879 (85.5) 0.0115* 40 (93.0) 795 (94.4) 0.7294a 
13 – 23 months 48 (16.0) 226 (10.3) 3 (7.0) 47 (5.6) 
24+ months 13 (4.3) 92 (4.2) 0 (0.0) 0 (0.0) 
 300 (100.0) 2197 (100.0)  43 (100.0) 842 (100.0)  
Year of Diagnosis       
88 – 07 11 (3.7) 104 (4.7) 0.6677 0 (0.0) 10 (1.2) 0.5995a 
08 – 12 117 (39.0) 870 (39.6) 4 (9.3) 51 (6.0) 
13 – 17 172 (57.3) 1223 (55.7) 39 (90.7) 781 (92.8) 
Total 300 (100.0) 2197 (100.0)  43 (100.0) 842 (100.0)  
Death       
Yes 176 (58.7) 1398 (63.6) 0.0947 10 (23.3) 241 (28.6) 0.4464 
No 124 (41.3) 799 (36.4) 33 (76.7) 601 (71.4) 
Total 300 (100.0) 2197 (100.0)  43 (100.0) 842 (100.0)  
afisher’s exact test used, *significant at 0.05 
bcolumn percentages presented 
ctotals do not equal the totals due to missing responses 
 
 
 
4.4.2 CSF Use vs Dose Reduction vs Both Characteristics and Comparisons  
Since some subjects received both CSF and dose reduction, characteristics were 
compared between subjects who received only CSF, versus subjects who received only 
dose reduction, versus subjects who received both CSF and dose reduction. As seen in the 
table below, 300 (46.7%) subjects received CSF, 298 (46.4%) subjects received dose 
reduction, while 44 subjects received both CSF and dose reduction (6.9%) in the pre-
period. The mean age of subjects who received dose reduction (71.0±8.0) and those who 
received both (70.3±3.2) was higher than those who received CSF (59.9±11.0). Table 4.5 
shows the characteristics of subjects for the three groups. 
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Table 4.5: Characteristics of CSF Users vs Dose Reduction vs Both in the Pre-Period 
Characteristica CSF Use Dose Reduction  Both Total P-Value 
Age, Mean (SD)  59.9 (11.0) 71.0 (8.0) 70.3 (3.2)  <0.0001* 
Gender, n (%)      
Female 142 (47.3) 123 (41.3) 24 (54.5) 289 (45.0) 0.1388 
Male 158 (52.7) 175 (58.7) 20 (45.5) 353 (55.0) 
Total 300 (100.0) 298 (100.0) 44 (100.0) 642   
Age Group, n (%)      
<60  148 (49.3) 19 (6.4) 3 (6.8) 170 (26.5) <0.0001* 
60 – 69 94 (31.3) 108 (36.2) 16 (36.4) 218 (34.0) 
70 – 79 44 (14.7) 129 (43.3) 24 (54.5) 197 (30.7) 
80 and above 14 (4.7) 42 (14.1) 1 (2.3) 57 (8.8) 
Total 300 (100.0) 298 (100.0) 44 (100.0) 642  
Disease, n (%)      
Colon  208 (69.3) 237 (79.5) 32 (72.7) 477 (74.3) 0.0166* 
Rectal 92 (30.7) 61 (20.5) 12 (27.3) 165 (25.7) 
Total 300 (100.0) 298 (100.0) 44 (100.0) 642  
Line of Therapy, 
n (%) 
     
1st line 180 (60.0) 212 (71.1) 32 (72.7) 424 (66.0) 0.0092* 
2nd line 101 (33.7) 66 (22.2) 12 (27.3) 179 (27.9) 
3rd line 12 (4.0) 18 (6.0) 0 (0.0) 30 (4.7) 
Beyond 3rd  7 (2.3) 2 (0.7) 0 (0.0) 9 (1.4) 
Total 300 (100.0) 298 (100.0) 44 (100.0) 642  
FN Risk, n (%)      
Low  131 (45.8) 138 (46.3) 20 (45.5) 289 (46.0) 0.9895 
Intermediate 155 (54.2) 160 (53.7) 24 (54.5) 339 (54.0) 
Totalc 286 (100.0) 298 (100.0) 44 (100.0) 628   
Duration of 
Treatment, n (%) 
     
0 – 12 months 239 (79.7) 232 (77.9) 32 (72.7) 503 (78.3) 0.0946 
13 – 23 months 48 (16.0) 38 (12.8) 7 (15.9) 93 (14.5) 
24+ months 13 (4.3) 28 (9.4) 5 (11.4) 46 (7.2) 
Total 300 (100.0) 298 (100.0) 44 (100.0) 642  
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Table 4.5: Characteristics of CSF Users vs Dose Reduction vs Both in the Pre-Period (Cont’d) 
Year of 
Diagnosis, n (%) 
     
88 – 07 11 (3.7) 17 (5.7) 1 (2.3) 29 (4.5) 0.6975 
08 – 12 117 (39.0) 115 (38.6) 19 (43.2) 251 (39.1) 
13 – 17 172 (57.3) 166 (55.7) 24 (54.5) 362 (56.4) 
Total 300 (100.0) 298 (100.0) 44 (100.0) 642   
Death, n (%)      
Yes 176 (58.7) 215 (72.1) 32 (72.7) 423 (65.9) 0.0015* 
No 124 (41.3) 83 (27.9) 12 (27.3) 219 (34.1) 
Total 300 (100.0) 298 (100.0) 44 (100.0) 642  
acolumn percentages presented, *significant at 0.05 
ctotals do not equal the totals due to missing responses 
 
 
4.5 OBJECTIVE 2: PREVALENCE AND PATTERNS OF CSF ADMINISTRATION 
The second objective was to determine the prevalence and patterns of CSF use and 
dose reduction in the population. While the first objective analyzed distinct CSF users, the 
analyses for this objective include all subjects who received CSF, with or without dose 
reduction. Results are reported by time periods. However, the study period was further 
divided into quarters, and the prevalence reported for each quarter. [See Tables 4.6 to 4.9]. 
4.5.1 Prevalence of CSF Use 
A total of 11% (N=387) of the population used CSF. Comparing time periods, the 
proportion of subjects who received CSF in the pre-period was higher (13.5%) than the 
proportion that received CSF in the post-period (4.9%) [See Table 4.6]. To better compare 
the frequencies across equal time periods, the pre-period was divided into three time 
periods of six months each. Comparing across the four time periods, the post-period quarter 
had the lowest proportion of CSF users [See Table 4.7].  
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Table 4.6: Frequency of CSF Use  
Variable Pre-period 
N (%) 
Post-Period 
N (%) 
Total 
Subjects who used CSF 344 (13.5) 43 (4.9) 387 (11.3) 
Subjects who did not use CSF 2197 (86.5) 842 (94.1) 3039 (88.7) 
Total 2541 885 3426 
 
Table 4.7: Frequency of CSF Use by Time Periods 
Variable Pre-period 
N (%) 
Post-period 
N (%) 
Total 
 July – Dec 
2013 
Jan – June 
2014 
July – Dec 
2014 
July – Dec 
2017 
 
 Period 1 Period 2 Period 3 Period 4  
Subjects who used CSF  117 (14.2) 121 (13.6) 106 (12.8) 43 (4.9) 387 
Subjects who did not use CSF 705 (85.8) 771 (86.4) 721 (87.2) 842 (95.1) 3039 
Total 822 892 827 885 3426 
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4.5.2 Prevalence of CSF Administrations 
There was a total of 3095 CSF administrations during the study period, with a mean 
of 0.90±3.71. The mean number of CSF administrations in the pre-period was higher 
(1.11±4.2) than that of the post-period (0.31±1.6) [See Table 4.8]. To better compare the 
frequencies across equal time periods, the pre-period was divided into three time periods 
of six months each. Comparing across the four time periods, the post-period had the lowest 
proportion of CSF administrations [See Table 4.9].  
Table 4.8: Frequency of CSF Administrations 
Variable Pre-period Post- Period Total 
Number of CSF administrations 2818 277 3095 
Mean (SD) number of CSF 
Administrations 
1.11 (4.2) 0.31 (1.6) 0.90 (3.71) 
 
 
Table 4.9: Frequency of CSF Administrations by Time Periods 
Variable Pre- period Post-period Total 
 July – Dec 
2013  
Jan – June 
2014 
July – Dec 
2014 
July – Dec 
2017 
 
 Period 1 Period 2 Period 3 Period 4  
Number of CSF Administrations 907 1162 749 277 3095 
Mean (SD) number of CSF 
Administrations 
1.10 (4.1) 1.30 (4.8) 0.91 (3.5) 0.31 (1.6)  
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Figure 4.1: CSF Use by Quarter 
 
 
 
Figure 4.2: CSF Administrations by Quarter 
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4.5.3 Prevalence of Dose Reduction 
The frequency of chemotherapy dose reduction was assessed, and this provided a 
comparison of patients who received CSF vs those who received dose reduction. However, 
the dose reduction variable was available for the pre-period data only and had a problem 
of missingness. So, this was assessed for subjects at baseline who had data on dose 
reduction. 
Of the 508 patients who had data on dose reduction use, 342 (67.32%) received 
dose reduction, while 166 (32.68%) did not. However, 44 (8.7%) of the patients received 
both CSF administration and dose reduction. 
Table 4.10: Prevalence of CSF Use vs Dose Reduction for the Pre-Period 
Variable CSF Use No CSF Use Total 
Dose Reduction 44 (8.7) 298 (58.7) 342 (67.32) 
No dose Reduction 12 (2.4) 154 (30.3) 166 (32.68) 
 56 452 508 
 
 
4.6 OBJECTIVE 3: IMPACT OF PROGRAM INITIATIVE ON CSF PRESCRIPTION 
PREVALENCE 
The third objective was to evaluate the effect of the program initiative on CSF use. 
Results are presented in Tables 4.11 and 4.12. 
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4.6.1 Checking Assumptions 
The assumptions of t-test analysis (independence, normality, equal variance) were 
checked prior to analyses. Although the variable CSF administrations was not normally 
distributed, the large sample size means that the data distribution should approach a normal 
distribution. As well, the t-test is fairly robust to the normality assumption so the deviation 
from normality would not largely impact type 1 error rates.132  The assumption of equal 
variance was not met, but this was corrected by using the Satterthwaite p-values instead of 
the pooled p-values to determine significance. On the contrary, the chi square assumptions 
of independence and expected cell counts were met.  
4.6.2 Analyses Results 
H1: CSF use will be significantly lower post-initiative compared to the pre-initiative 
period. 
Results showed a significant difference in means of CSF administrations between 
the pre- and post-periods (t=8.05, p<0.0001). The pre-period had significantly higher mean 
CSF administration (1.11±4.19) than the post-period (0.31±1.60). Also, the maximum 
number of administrations a patient received in the pre-period was higher than that of the 
post-period (58 vs 13) [See Table 4.11].  
Likewise, there was a significant difference in proportion of patients that used CSF 
in the pre-period compared to the post-period (X2=4.93, p<0.0001). The pre-period had a 
significantly higher proportion of CSF users (13.5%) than the post-period (4.9%) [See 
Table 4.12].  Given the results, H1 was supported. 
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Table 4.11: Impact of Program Initiative on CSF Administrations 
 Pre-period 
(N=2541) 
Post- Period 
(N=885) 
T-statistic P-value 
Number of CSF Administrations 2818 277 8.05 <0.0001 
Mean (SD) number of CSF 
administrations 
1.11 (4.19) 0.31 (1.60) 
Maximum Administrations a patient 
received 
58 13 
 
 
Table 4.12: Impact of Program Initiative on CSF Use 
 Pre-period 
N= 2541 
Post-Period 
N=885 
X2-statistic P value 
Subjects who used CSF, N (%) 344 (13.5) 43 (4.9) 49.35 <0.0001 
Subjects who did not use CSF, N (%) 2197 (86.5) 842 (95.1) 
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4.7 OBJECTIVE 4: IMPACT OF PROGRAM INITIATIVE ON COMPLIANCE TO ASCO 
GUIDELINES 
The fourth objective was to assess the impact of a program initiative on compliance 
to ASCO guidelines on CSF use. Only low and intermediate risk regimens were found in 
the data set; hence patients were deemed compliant if they did not receive CSF.  
H2: Compliance will be significantly higher post-initiative compared to the pre-
initiative period. 
The proportion of patients who did not receive CSF medication in the post-period was 
higher (95.1%) than the proportion that did not receive in the pre-period (86.5), and this 
difference was significant (p<0.0001). Given the results, H2 was supported. [ 
Table 4.13: Impact of Program Initiative on Compliance 
 Pre-period 
N= 2541 
Post-Period 
N=885 
X2-statistic P value 
Subjects who used CSF, N (%) 344 (13.5) 43 (4.9) 49.35 <0.0001 
Subjects who did not use CSF, N 
(%) 
2197 (86.5) 842 (95.1) 
 
 
4.8 OBJECTIVE 5: PREDICTORS OF CSF USE 
The fifth objective was to determine the relationships between CSF use (dependent 
variable) and the variables age, FN risk and year of diagnosis (primary predictors), while 
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controlling for gender, disease, line of therapy and duration of treatment (covariates). The 
relationships were assessed using logistic regression models and for the pre-period data.  
4.8.1 Checking Assumptions 
Each assumption of logistic regression analysis (independence of errors, linearity 
in logit, absence of multicollinearity and large sample size) was checked prior to analyses. 
The results showed that none of the assumptions were violated [See Appendix B].  
4.8.2 Univariate Logistic Models 
Univariate logistic analysis was conducted for each predictor [See Table 4.14]. 
Variables with significant model p-values were selected for the multivariate analysis. All 
the variables had model p-values below 0.05 except for year of diagnosis and disease, 
hence they were removed from the model for the multivariate analysis.  
Table 4.14 Logistic Regression Analysis of Factors Associated with CSF Use in the Pre-Period 
(Unadjusted)  
Variable 
 
Wald’s X2 P-Value  Odds Ratio 95% C.I. of OR 
Lower Limit Upper Limit 
FN Risk 
(ref=Low) 
     
Intermediate 16.11 <0.0001 1.66 1.30 2.13 
Age 
(ref = <60 years) 
     
60 – 69 years 1.70 0.1921 0.83 0.63 1.10 
70 – 79 years 9.67 0.0019 0.57 0.40 0.81 
80+ years 5.32 0.0211 0.51 0.29 0.90 
Duration of Treatment 
(ref = 0 - 12 months) 
     
13 – 23 months 8.77 0.0031 1.67 1.20 2.34 
24+ months 0.12 0.7295 1.11 0.61 2.02 
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Table 4.14 Logistic Regression Analysis of Factors Associated with CSF Use in the Pre-Period 
(Unadjusted) (Cont’d) 
Line of Therapy 
(ref= 1st line) 
     
2nd line 0.24 0.6239 1.07 0.82 1.39 
3rd line 10.76 0.0010 0.36 0.20 0.67 
Beyond 3 0.36 0.5496 0.78 0.35 1.74 
Year of Diagnosis 
(ref= 88 – 07) 
     
08 – 12 0.52 0.4698 1.27 0.66 2.44 
13 – 17  0.76 0.3844 1.33 0.70 2.53 
Gender 
(ref=Male) 
     
Female 5.90 0.0151 1.35 1.06 1.72 
Disease 
(ref= Rectal Cancer) 
     
Colon Cancer 2.72 0.0993 1.25 0.96 1.62 
 
4.8.3 Multivariate Logistic Model 
The adjusted logistic model was fit using all covariates that were significant in the 
univariate analysis at the 5% level. Due to this, all variables except for year of diagnosis 
and disease were retained for the multivariate analysis. Overall, the logistic regression 
model was statistically significant at X2=63.68; p<0.0001. The results showed a 
statistically significant relationship between CSF use and the predictors age and FN risk 
controlling for covariates. A statistically significant relationship was also seen with CSF 
use and the covariates gender, line of therapy and duration of treatment. 
H3a: Age is negatively associated with CSF use after adjusting for covariates. 
Younger subjects are more likely to receive CSF compared to older subjects. 
 Age was significantly related to CSF use. The odds of using CSF decreased as age 
increased. Compared to subjects who were below 60 years, subjects who were in the 70-
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79 age group had about 41% decreased odds of using CSF (X2=8.32; OR=0.59; 95% CI= 
0.41, 0.84; p = 0.0039), and subjects who were in the 80+ age group had 56% decreased 
odds of using CSF (X2=6.87; OR=0.44; 95% CI= 0.24, 0.81; p= 0.0088). There was no 
significant difference between subjects who were less than 60 years of age and those in the 
60-69 age group (X2=2.04; OR=0.81; 95% CI= 0.61, 1.08; p = 0.1528). Given the results, 
H3a was supported.  
H3b: FN risk is positively associated with CSF use after adjusting for covariates. 
Subjects with higher FN risk will be more likely to use CSF compared to subjects with 
lower FN risk. 
 The results show that FN risk was significantly related to CSF use. Compared to 
subjects who had low FN risk, the odds that subjects with an intermediate FN risk received 
CSF was higher by 83% (X2=15.24; OR=1.83; 95% CI= 1.35, 2.48; p < 0.0001).  Given 
the results, H3b was supported.  
H3c: Year of diagnosis is positively associated with CSF use after adjusting for 
covariates. Subjects diagnosed in recent years are more likely to use CSF compared 
to subjects diagnosed in former years. 
 Year of diagnosis was not significantly related to CSF use. In the univariate 
analysis, there was no significant difference in CSF use between subjects diagnosed in 
1988-2007 and subjects diagnosed in 2008 – 2012 (X2=0.52; OR=1.27; 95% CI= 0.66, 
2.44; p =0.4698) or subjects diagnosed in 2013 – 2017 (X2=0.76; OR=1.33; 95% CI= 0.70, 
2.53; p =0.3844).  Given the results, H3c was not supported.  
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Covariates 
 Among the covariates, gender, duration of treatment and line of therapy were 
significantly associated with CSF use. Females had significantly higher odds of using CSF 
compared to males (X2=5.88; OR=1.37; 95% CI= 1.06, 1.75; p = 0.0153). Compared to 
patients whose duration of treatment was 0-12 months, subjects whose duration of 
treatment was 13-23 months had 60% increased odds of CSF use (X2=6.67; OR=1.60; 95% 
CI= 1.12, 2.28; p = 0.0098). There was no significant difference in CSF use between 
subjects with 0-12 months duration and subjects with 24+ months duration (X2=0.07; 
OR=1.08; 95% CI= 0.59, 1.98; p = 0.7934).  For line of therapy, subjects who received a 
2nd line of therapy had 56% higher odds of using CSF (X2=7.33; OR=1.56; 95% CI= 1.13, 
2.15; p = 0.0068) than subjects who received a 1st line of therapy. Conversely, subjects 
who received a 3rd line of therapy had 52% lower odds of using CSF (X2=4.50; OR=0.48; 
95% CI= 0.24, 0.95; p = 0.0338) than subjects who received a 1st line of therapy. However, 
there was no significant difference in CSF use between subjects who received a 1st line of 
therapy and subjects who had beyond the 3rd line of therapy (X2=1.77; OR=0.45; 95% CI= 
0.14, 1.46; p = 0.1835).  
Table 4.15: Logistic Regression Analysis of Factors Associated with CSF Use  in the Pre-
Period(Adjusted) 
Variable 
 
Wald’s X2 P-Value  Odds Ratio 95% Confidence Interval of OR 
Lower Limit Upper Limit 
FN Risk 
(ref=Low) 
     
Intermediate 15.24 <0.0001* 1.83 1.35 2.48 
Age 
(ref = <60 years) 
     
60 – 69 years 2.04 0.1528 0.81 0.61 1.08 
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Table 4.15: Logistic Regression Analysis of Factors Associated with CSF Use  in the Pre-
Period(Adjusted) (Cont’d) 
70 – 79 years 8.32 0.0039* 0.59 0.41 0.84 
80+ years 6.87 0.0088* 0.44 0.24 0.81 
Duration of Treatment 
(ref = 0 - 12 months) 
     
13 – 23 months 6.67 0.0098* 1.60 1.12 2.28 
24+ months 0.07 0.7934 1.08 0.59 1.98 
Line of Therapy 
(ref= 1st line) 
     
2nd line 7.33 0.0068* 1.56 1.13 2.15 
3rd line 4.50 0.0338* 0.48 0.24 0.95 
Beyond 3 1.77 0.1835 0.45 0.14 1.46 
Gender 
(ref=Male) 
     
Female 5.88 0.0153* 1.37 1.06 1.75 
Model LR X2=63.69; DF=10; p< 0.0001 
*significant at p<0.05 
 
4.8.4 Predictors of CSF Use in the Post-Period 
For comparison, logistic regression models were also employed to assess the 
predictors of CSF use in the post-period. The assumptions for multicollinearity were 
equally tested, and none of the assumptions were violated [see Appendix B]. Univariate 
analysis was conducted for each predictor. Variables were checked for significance. 
However, all the variables (age, duration of treatment, line of therapy, year of diagnosis 
FN risk, gender and disease) had model p-values above 0.05 and hence a multivariate 
model could not be fit. There was no significant predictor of CSF use in the post-period. 
[see Table 4.16].  
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Table 4.16: Logistic Regression Analysis of Factors Associated with CSF Use in the 
Post-Period (Unadjusted)  
Variable 
 
Wald’s X2 P-Value  Odds Ratio 95% Confidence Interval of OR 
Lower Limit Upper Limit 
FN Risk 
(ref=Low) 
     
Intermediate 3.16 0.0754 1.76 0.94 3.27 
Age 
(ref = <60 years) 
     
60 – 69 years 2.33 0.1270 0.56 0.26 1.18 
70 – 79 years 1.07 0.3015 0.64 0.27 1.50 
80+ years 1.31 0.2519 0.31 0.04 2.31 
Duration of 
Treatment 
(ref = 0 - 12 months) 
     
13 – 23 months 0.15 0.6995 1.27 0.38 4.25 
24+ months - - - - - 
Line of Therapy 
(ref= 1st line) 
     
2nd line 1.52 0.2179 0.62 0.29 1.33 
3rd line 0.79 0.3751 0.52 0.12 2.22 
Beyond 3 0.16 0.6881 1.53 0.19 12.24 
Year of Diagnosis 
(ref= 88 – 07) 
     
08 – 12 0.00 0.9742 >999 <0.001 >999 
13 – 17  0.00 0.9752 >999 <0.001 >999 
Gender 
(ref=Male) 
     
Female 1.68 0.1949 1.50 0.81 2.77 
Disease 
(ref= Rectal Cancer) 
     
Colon Cancer 0.24 0.6223 0.83 0.39 1.76 
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4.9 OBJECTIVE 6: PREDICTORS OF DOSE REDUCTION 
The sixth objective was to determine the relationships between dose reduction 
(dependent variable) and the variables age and FN risk (primary predictors), while 
controlling for gender, disease, line of therapy, year of diagnosis and duration of treatment. 
The relationships were assessed using logistic regression models. Univariate logistic 
analysis was conducted with each predictor, then the multivariate logistic analysis was 
conducted with important covariates. The dependent variable dose reduction was 
dichotomized as 1=yes vs 0=no. The probability modeled was dose reduction=1.  
4.9.1 Checking Assumptions 
The logistic assumptions (independence, linearity in logit, no multicollinearity and 
large sample size) that were checked prior to analyses in section 4.8 were valid for the 
analyses. However, since there was a new dependent variable (dose reduction), the variance 
inflation factor (VIF) and tolerance were assessed. The results showed that none of the 
assumptions were not violated [See Appendix B].  
4.9.2 Univariate Logistic Models 
Univariate logistic analysis was conducted for each predictor [See Table 4.17]. 
Significant variables were selected for the multivariate analysis. The variables age, 
diagnosis, gender, line of therapy and disease had model p-values above 0.05 and hence 
were removed from the model for the multivariate analysis.  
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Table 4.17: Logistic Regression Analysis of Factors Associated with Dose Reduction 
(Unadjusted)  
Variable 
 
Wald’s X2 P-Value  Odds Ratio 95% Confidence Interval of OR 
Lower Limit Upper Limit 
FN Risk 
(ref=Low) 
     
Intermediate 12.11 0.0005 1.99 1.35 2.95 
Age 
(ref = <60 years) 
     
60 – 69 years 0.004 0.9521 1.03 0.46 2.30 
70 – 79 years 0.09 0.7619 1.13 0.50 2.52 
80+ years 0.10 0.7542 0.87 0.36 2.10 
Duration of 
Treatment 
(ref = 0 - 12 months) 
     
13 – 23 months 9.32 0.0023 3.65 1.59 8.38 
24+ months 8.88 0.0029 6.28 1.88 21.00 
Line of Therapy 
(ref= 1st line) 
     
2nd line 0.62 0.4319 0.83 0.53 1.31 
3rd line 1.33 0.2495 0.65 0.31 1.36 
Beyond 3 3.58 0.0584 0.20 0.04 1.06 
Year of Diagnosis 
(ref= 88 – 07) 
     
08 – 12 0.00 0.9632 1.02 0.45 2.30 
13 – 17  0.43 0.5101 1.31 0.59 2.93 
Gender 
(ref=Male) 
     
Female 0.68 0.4079 1.18 0.79 1.74 
Disease 
(ref= Rectal Cancer) 
     
Colon Cancer 1.80 0.1793 0.74 0.47 1.15 
 
4.9.3 Multivariate Logistic Model 
The adjusted logistic model was fit using the covariates that were significant in the 
univariate analysis at the 5% level. Overall, the logistic regression model was statistically 
significant at X2=35.47; p<0.0001. The results showed a statistically significant 
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relationship between dose reduction and the predictor FN risk. A statistically significant 
relationship was also seen with dose reduction and the covariate duration of treatment. 
Results are presented in table 4.18.  
H4a: Age is positively associated with dose reduction after adjusting for covariates. 
Older subjects are more likely to receive dose reduction compared to younger 
subjects. 
 Age was not related to dose reduction. The univariate results showed that there was 
no significant difference in dose reduction between subjects who were less than 60 years 
of age and those in the 60-69 age group (X2=0.00; OR=1.03; 95% CI= 0.46, 2.30; p = 
0.9521), those in the 70-79 age group (X2=0.09; OR=1.13; 95% CI= 0.51, 2.52; p = 
0.7619), and those in the 80+ age group (X2=0.09; OR=0.87; 95% CI= 0.36, 2.10; p = 
0.7542). Given the results, H4a was not supported.  
H4b: FN risk is positively associated with dose reduction after adjusting for 
covariates. Subjects with higher FN risk will be more likely to receive dose reduction 
compared to subjects with lower FN risk. 
 The results show that FN risk was significantly related to dose reduction. Compared 
to subjects who had low FN risk, subjects with an intermediate FN risk were about two 
times as likely to receive dose reduction  (X2=11.57; OR=1.99; 95% CI= 1.34, 2.97; p 
=0.0007).  Given the results, H4b was supported.  
Covariates 
 Among the covariates, only duration of treatment was significantly associated with 
dose reduction. Compared to patients whose duration of treatment was 0-12 months, 
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subjects whose duration of treatment was 13-23 months were over three times more likely 
to receive dose reduction (X2=9.38; OR=3.71; 95% CI= 1.60, 10.24; p = 0.0022). Likewise, 
subjects whose duration of treatment was 24+ months had even higher odds of receiving 
dose reduction (X2=8.61; OR=6.16; 95% CI= 1.83, 20.74; p =0.0034).   
 
Table 4.18: Logistic Regression Results of Factors Associated with Dose Reduction 
(Adjusted) 
Variable 
 
Wald’s X2 P-Value  Odds Ratio 95% Confidence Interval of OR 
Lower Limit Upper Limit 
FN Risk 
(ref=Low) 
     
Intermediate 11.57 0.0007* 1.99 1.34 2.97 
Duration of Treatment 
(ref = 0 – 12 months) 
     
13 – 23 months 9.38 0.0022* 3.71 1.60 8.57 
24+ months 8.61 0.0034* 6.16 1.83 20.74 
Model X2=34.86; DF=3; p< 0.0001 
*significant at p<0.05 
 
4.10 OBJECTIVE 7: FACTORS ASSOCIATED WITH ALL-CAUSE MORTALITY 
The seventh objective was to evaluate the effects of covariates on a health outcomes 
index (all-cause mortality) in the population. This was addressed using the pre-period 
cohort, due to the longer follow up period that allows for a possible mortality outcome. 
Logistic regression analyses were used to address this objective. The outcome of interest 
was all-cause mortality, while the primary predictors of interest were age, CSF use and 
dose reduction. The covariates included were FN risk, gender, duration of treatment, line 
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of therapy, disease and year of diagnosis. The dependent variable mortality was 
dichotomized as 1=yes and 0=no, and the probability modeled was mortality=1. The 
primary predictor CSF use was dichotomous (1=CSF use vs 0=no CSF use), while dose 
reduction was dichotomous (1=yes and 0=no).   
4.10.1 Checking Assumptions 
Again, the logistic regression analysis assumptions (independence of errors, 
linearity in logit, absence of multicollinearity and absence of strong outliers) were checked 
prior to analyses. The spearman correlation matrix including all predictors was assessed 
since all predictors were categorical variables. All results showed no violations in 
assumptions [See Appendix B]. 
4.10.2 Univariate Model 
Univariate analyses were first run to identify important covariates for the 
multivariate models. The variables CSF use, disease and year of diagnosis were excluded 
from the adjusted analysis. Also, dose reduction was run as a separate model in the adjusted 
analyses due to data missingness. In summary, the main adjusted model was run first, while 
the second adjusted model was run with dose reduction as a primary predictor. Results of 
the unadjusted analyses are presented in Table 4.19, while those of the adjusted analysis 
are presented in Tables 4.20 and 4.21. 
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Table 4.19 Logistic Regression Results of Factors Associated with All-Cause Mortality 
(Unadjusted) 
Variable 
 
Wald’s X2 P-Value  Odds 
Ratio 
95% Confidence Interval of OR 
Lower Limit Upper Limit 
CSF Use 
(ref= no CSF use) 
     
CSF Use 2.79 0.0951 0.81 0.63 1.04 
FN Risk 
(ref=Low) 
     
Intermediate 32.56 <0.0001 0.62 0.53 0.73 
Age 
(ref = <60 years) 
     
60 – 69 years 6.54 0.0106 1.28 1.06 1.54 
70 – 79 years 45.90 <0.0001 2.20 1.75 2.76 
80+ years 40.31 <0.0001 3.67 2.46 5.48 
Duration of Treatment 
(ref = 0 - 12 months) 
     
13 – 23 months 0.40 0.5265 0.920 0.71 1.19 
24+ months 28.83 <0.0001 0.34 0.23 0.50 
Line of Therapy 
(ref= 1st line) 
     
2nd line 56.22 <0.0001 2.05 1.70 2.48 
3rd line 38.58 <0.0001 2.76 2.00 3.80 
Beyond 3 12.74 0.0004 2.88 1.61 5.15 
Gender 
(ref=Male) 
     
Female 14.02 0.0002 0.73 0.62 0.86 
Disease 
(ref= Rectal Cancer) 
     
Colon Cancer 1.28 0.2587 1.11 0.93 1.33 
Year of Diagnosis 
(ref = 88-07) 
     
08 – 12 2.44 0.1182 0.71 0.47 1.10 
13 – 17  4.29 0.0383 0.64 0.42 0.98 
Dose Reduction 
(ref=No) 
     
Yes 8.59 0.0034 0.48 0.30 0.79 
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4.10.3 Multivariate Models 
Overall, the multivariate logistic regression model was statistically significant at 
X2=221.58; p<0.0001. The results showed a statistically significant relationship between 
mortality and the predictor age. A statistically significant relationship was also seen with 
mortality and the covariates gender, line of therapy and duration of treatment.  
H5a: Age is positively associated with mortality after adjusting for covariates. Older 
subjects will have higher odds of death compared to younger subjects. 
 Age showed a significant relationship with mortality. As age of subject increased, 
the odds of death increased. Compared to subjects who were less than 60 years, subjects in 
the 60-69 age group had 39% higher odds of death (X2=10.50; OR=1.39; 95% CI= 1.14, 
1.70; p=0.0012). Similarly, subjects in the 70-79 age group were more than twice as likely 
to die (X2=53.85; OR=2.44; 95% CI= 1.92, 3.09; p<0.0001), while subjects who were 80 
years and above were more than four times as likely to die (X2=46.04; OR=4.15; 95% CI= 
2.75, 6.27; p<0.0001). Given the results, H5a was supported.  
H5b: CSF use is negatively associated with mortality after adjusting for covariates. 
Subjects who received CSF will have lower odds of death compared to subjects who 
did not receive CSF. 
 CSF use was not significantly related with mortality. The univariate analysis 
showed no difference in odds of death between people who used CSF and people who did 
not (X2=2.79; OR=0.81; 95% CI= 0.63, 1.04; p=0.0951) [See Table 4.19] hence CSF use 
was not included in the multivariate analysis. Given the results, H5b was not supported. 
 124 
H5c: Dose reduction is positively associated with mortality after adjusting for 
covariates. Subjects who received dose reduction will have lower odds of death than 
those who did not. 
 Dose reduction was not significantly related with mortality. There was no 
difference in odds of death between people who received dose reduction and people who 
did not (X2=2.70; OR=0.64; 95% CI= 0.38, 1.09; p=0.1002)  [See Table 4.21]. Given the 
results, H5c was not supported. 
Covariates 
 Among the covariates (based on the main model), duration of treatment, line of 
therapy and gender showed significant association with mortality. As line of therapy 
increased, odds of death increased. Compared to subjects who received the 1st line of 
chemotherapy, subjects who received the 2nd line of therapy had 97 percent higher 
likelihood of death (X2=10.50; OR=1.97; 95% CI= 1.58, 2.46; p=0.0012), subjects who 
received the 3rd line of therapy had even higher odds of death (X2=53.85; OR=2.67; 95% 
CI= 1.89, 3.83; p<0.0001), while subjects whose therapy was beyond the 3rd line were more 
than 4 times more likely to die (X2=46.04; OR=4.39; 95% CI= 2.18, 8.85; p<0.0001).  
Compared to subjects who had 0-12 months duration of treatment, subjects who had 24+ 
months duration of treatment had a 64 percent decreased odds of death (X2=23.59; 
OR=0.36; 95% CI= 0.24, 0.54; p<0.0001). There was no statistical difference in odds of 
death between those who had 0-12 months duration of treatment and those with 13-23 
months duration of treatment (X2=0.03; OR=1.03; 95% CI= 0.78, 1.35; p=0.8521). For 
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gender, females had significantly lower odds of death compared to males (X2=12.53; 
OR=0.73; 95% CI= 0.62, 0.87; p = 0.0004)  [See Table 4.20]. 
Table 4.20: Logistic Regression Results of Factors Associated with All-Cause Mortality 
(Adjusted) 
Variable 
 
Wald’s X2 P-Value  Odds Ratio 95% Confidence Interval of OR 
Lower Limit Upper Limit 
FN Risk 
(ref=Low) 
     
Intermediate 0.71 0.4005 0.92 0.75 1.12 
Age 
(ref = <60 years) 
     
60 – 69 years 10.50 0.0012* 1.39 1.14 1.69 
70 – 79 years 53.85 <0.0001* 2.44 1.92 3.10 
80+ years 46.04 <0.0001* 4.16 2.75 6.27 
Duration of Treatment 
(ref = 0 - 12 months) 
     
13 – 23 months 0.03 0.8521 1.03 0.78 1.35 
24+ months 23.59 <0.0001* 0.41 0.24 0.54 
Line of Therapy 
(ref= 1st line) 
     
2nd line 36.80 <0.0001* 1.97 1.58 2.46 
3rd line 32.41 <0.0001* 2.69 1.89 3.83 
Beyond 3 18.50 <0.0001* 4.39 2.18 8.85 
Gender 
(ref=Male) 
     
Female 12.53 0.0004* 0.73 0.62 0.87 
Model LR X2=221.58; DF=10; p< 0.0001 
*significant at p<0.05 
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Table 4.21: Logistic Regression Results of Factors Associated with All-Cause Mortality 
with Dose Reduction as Primary Predictor (Adjusted) 
Variable 
 
Wald’s X2 P-Value  Odds Ratio 95% Confidence Interval of OR 
Lower Limit Upper Limit 
Dose Reduction 
(ref= No dose reduction) 
     
 Dose Reduction 2.70 0.1002 0.64 0.38 1.09 
FN Risk 
(ref=Low) 
     
Intermediate 3.75 0.0529 0.60 0.35 1.00 
Age 
(ref = <60 years) 
     
60 – 69 years 0.05 0.8272 0.90 0.35 2.31 
70 – 79 years 0.72 0.3964 1.50 0.59 3.85 
80+ years 2.88 0.0897 2.63 0.86 8.03 
Duration of Treatment 
(ref = 0 - 12 months) 
     
13 – 23 months 6.51 0.0107* 0.40 0.20 0.89 
24+ months 7.48 0.0062 0.32 0.15 0.73 
Line of Therapy 
(ref= 1st line) 
     
2nd line 4.29 0.0384* 2.12 1.04 4.31 
3rd line 0.28 0.6000 1.33 0.46 3.87 
Beyond 3 0.54 0.4637 2.28 0.25 20.58 
Gender 
(ref=Male) 
     
Female 5.89 0.0152* 0.56 0.36 0.89 
Model LR X2=52.64; DF=11; p< 0.0001 
*significant at 0.05 
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4.11 OBJECTIVE 8: COMPARATIVE EFFECTIVENESS OF CSF USE VS DOSE 
REDUCTION ON ALL-CAUSE MORTALITY 
The eighth objective was to compare the effect of  CSF use on all-cause mortality 
to the effect of dose reduction on all-cause mortality in the population. This was addressed 
using the pre-period cohort as well, because the pre-period has the dose reduction variable. 
The variable ‘compare’ used for this objective, was a categorical variable with two levels; 
0=dose reduction and 1=CSF use.  
4.11.1 Checking Assumptions 
For models with CSF use and dose reduction, the logistic regression assumptions 
already assessed in objective 7 [see section 4.10] were valid for this analysis. For the new 
variable compare, the correlation matrix including all predictors including ‘compare’ was 
assessed. The results showed that none of the assumptions were violated. [See Appendix 
B] 
4.11.2 Univariate Logistic Models 
All univariate analyses for the mortality outcome were conducted in section 4.10 
and results displayed in Table 4.19. However, univariate results for CSF use and dose 
reduction are equally shown in this section for better comparison against the variable 
‘compare’ [See Table 4.22].  
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4.11.3 Multivariate Logistic Model 
The multivariate model comparing the effect of CSF use vs dose reduction on all-
cause mortality was significant at X2=93.08, p<0.0001. The results showed no statistical 
association between the compare variable and mortality [See Table 4.23]. 
H6: The variable ‘compare’ (CSF Use vs Dose Reduction) is not significantly 
associated with mortality after adjusting for covariates. There will be no difference 
in odds of death between subjects who received CSF and subjects who received dose 
reduction.  
 The variable ‘compare’ (CSF Use vs Dose Reduction) was not significantly 
associated with mortality after model adjustment. There was no difference in odds of death 
between people who received dose reduction and those who received CSF (X2=1.31; 
OR=0.78; 95% CI= 0.50, 1.20; p=0.2524).  Given the results, H6 was supported. [See Table 
4.23]. 
Table 4.22: Logistic Regression Results of CSF Use, Dose Reduction and ‘Compare’ on All-
Cause Mortality (Unadjusted) 
Variable 
 
Wald’s X2 P-Value  Odds Ratio 95% Confidence Interval of OR 
Lower Limit Upper Limit 
CSF Use 
(ref= no CSF use) 
     
CSF Use 2.79 0.0951 0.81 0.63 1.04 
Dose Reduction 
(ref = no dose 
reduction) 
     
Dose Reduction 8.59 0.0030 0.48 0.30 0.78 
Compare 
(ref = Dose 
Reduction) 
     
CSF Use 11.88 0.0006 0.55 0.39 0.77 
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Table 4.23: Logistic Regression Results of CSF Use vs Dose Reduction on All-Cause Mortality 
(Adjusted) 
Variable 
 
Wald’s X2 P-Value  Odds Ratio 95% Confidence Interval of OR 
Lower Limit Upper Limit 
CSF Use 
(ref= no CSF use) 
     
CSF Use 0.17 0.6763 0.95 0.73 1.23 
Dose Reduction 
(ref = no dose 
reduction) 
     
Dose Reduction 2.70 0.1002 0.64 0.38 1.09 
Compare 
(ref = Dose Reduction) 
     
CSF Use 1.31 0.2524 0.78 0.50 1.20 
 
Table 4.24: Logistic Regression Results of variable ‘Compare’ (CSF Use vs Dose  Reduction) on 
All-Cause Mortality (Adjusted) 
Variable 
 
Wald’s 
X2 
P-Value  Odds Ratio 95% Confidence Interval of OR 
Lower Limit Upper Limit 
Compare 
(ref= Dose reduction) 
     
 CSF Use 1.31 0.2524 0.78 0.50 1.20 
FN Risk 
(ref=Low) 
     
Intermediate 0.43 0.5137 0.87 0.56 1.34 
Age 
(ref = <60 years) 
     
60 – 69 years 7.56 0.0060 1.98 1.22 3.21 
70 – 79 years 17.50 <0.0001 3.31 1.90 5.81 
80+ years 15.86 <0.0001 6.08 2.50 14.77 
Duration of Treatment 
(ref = 0 - 12 months) 
     
13 – 23 months 0.00 0.9915 1.00 0.59 1.71 
24+ months 10.27 0.0014 0.31 0.15 0.64 
Line of Therapy 
(ref= 1st line) 
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Table 4.24: Logistic Regression Results of variable ‘Compare’ (CSF Use vs Dose  Reduction) on 
All-Cause Mortality (Adjusted) (Cont’d) 
2nd line 8.82 0.0030 2.13 1.29 3.50 
3rd line 1.35 0.2446 1.80 0.67 4.85 
Beyond 3 0.03 0.9867 >999 <0.01 >999 
Gender 
(ref=Male) 
     
Female 17.65 <0.0001 0.45 0.31 0.65 
Model LR X2=93.08; DF=11; p< 0.0001 
 
A summary of all objectives, hypotheses tests results, and the corresponding statistical 
decisions is presented in Table 4.25. 
 
Table 4.25: Results and Statistical Decisions of Hypothesis Tests 
Objectives/Hypotheses Statistical Test Results Statistical Decision 
Objective1: To describe the 
characteristics of CSF users in a 
cohort of metastatic colorectal 
cancer patients 
 
Descriptive Statistics N/A N/A 
Objective2: To describe the 
prevalence and patterns of CSF 
use and dose reduction in a 
cohort of metastatic colorectal 
cancer patients 
Descriptive Statistics N/A N/A 
Objective 3: To evaluate the impact of a program initiative on CSF prescription prevalence 
H1: CSF use will be 
significantly lower post-initiative 
compared to the pre-initiative 
period 
 
t-test and chi-square 
test 
Significant reduction 
found 
Supported 
Objective 4: To evaluate the impact of a program initiative on compliance to guidelines  
H2: Compliance to guidelines on 
CSF use will be significantly 
higher post-initiative compared 
to the pre-initiative period 
t-test Significant increase 
in compliance found 
Supported 
Objective 5: To determine the relationship between CSF use (dependent variable) and the variables 
age, FN Risk and Year of Diagnosis, while controlling for covariates 
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Table 4.25: Results and Statistical Decisions of Objectives’ Hypothesis Tests (Cont’d) 
H3a: Age is negatively 
associated with CSF use after 
adjusting for covariates 
 
Logistic Regression (-) association Supported 
H3b: FN risk is positively 
associated with CSF use after 
adjusting for covariates. 
Logistic Regression (+) association Supported 
H3c: Year of Diagnosis is 
positively associated with CSF 
use after adjusting for covariates. 
Logistic Regression No association Not Supported 
Significant Covariates: Female gender- (+) association; duration of treatment- (+) association; line of 
therapy- (+) and (-) association 
Objective 6: To determine the relationship between dose reduction (dependent variable) and the 
variables age and FN Risk while controlling for covariates 
 
H4a: Age is positively associated 
with dose reduction after 
adjusting for covariates 
 
Logistic Regression No association Not supported 
H4b: FN risk is positively 
associated with dose reduction 
after adjusting for covariates 
 
Logistic Regression (+) association Supported 
Significant Covariates: Duration of treatment- (+) association 
Objective 7: To determine the relationship between all-cause mortality (dependent variable) and the 
variables age, CSF use and dose reduction, while controlling for covariates 
 
H5a: Age is positively associated 
with mortality after adjusting for 
covariates. 
Logistic Regression (+) association Supported 
H5b: CSF use is negatively 
associated with mortality after 
adjusting for covariates. 
Logistic Regression No association Not supported 
H5c: Dose reduction is 
negatively associated with 
mortality after adjusting for 
covariates. 
Logistic Regression No association Not supported 
Significant  Covariates: Line of therapy- (+) association; duration of treatment- (-) association; Female 
gender- (-) association 
Objective 8: To compare the effect of  CSF use to the effect of dose reduction on all-cause mortality 
in the population. 
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H6: CSF Use vs Dose Reduction 
is not significantly associated 
with mortality after adjusting for 
covariates 
Logistic Regression No association Supported 
(+)= positive, (-)=negative  
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CHAPTER 5: DISCUSSION 
 This chapter discusses the findings of this study. The opening section gives an 
overview of the study. The next sections explain the findings as well as related findings 
from previous research, while the last sections discuss the study limitations and implication 
and give suggestions for future research.  
5.1 STUDY OVERVIEW 
 This study was aimed at describing the characteristics of patients who used CSF 
medications in a population of metastatic colorectal cancer patients, and the prevalence and 
patterns of CSF administration in the population. The study also assessed the impact of a 
program initiative on CSF use, as well as compliance to guidelines on CSF use. In addition, 
the  study evaluated the factors associated with CSF use, factors associated with dose 
reduction and factors associated with mortality. The study equally compared the impact of 
CSF use to dose reduction on a health outcomes index (all-cause mortality). While some 
studies have assessed CSF utilization and patterns of use among patients with various 
cancers, there are limited studies that have examined CSF use in metastatic cancer patients. 
Also, there is scant information in the literature about factors associated with dose 
reduction and all-cause mortality in such populations. To our knowledge, this is the first 
study that compares dose reduction to CSF administration and how they impact mortality. 
This study answers the research questions using data from a multi-center oncology practice 
network. In comparing this work to the literature, there are some differences that should be 
noted: i) The G-CSF medication in this study was pegfilgrastim (Neulasta); ii) This study 
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assessed a metastatic population; and iii) The intent of the CSF administration (whether 
prophylactic or reactive) was unknown. 
5.2 DISCUSSION 
5.2.1 Characteristics of CSF Users and Patterns of Use 
 Overall, CSFs were moderately utilized in this population. The proportion of 
patients that used CSF distinctively (i.e., without receiving dose reduction) was 10 percent 
(N=343). Of these, 45 percent of the patients had low FN risk while 55 percent had 
intermediate FN risk. This was anticipated, as patients with higher risk regimens are more 
prone to FN, thus more likely to receive growth factors. These findings support extant 
literature. A population-based cohort study found  moderate to high use of CSF  (range  9 
- 33%) among patients with various cancers, with 9% use amongst the colorectal cancer 
patients.21 Another recent study that reviewed the Medicare database to assess use of 
growth factors in different cancers found most CSF use occurring among higher FN risk 
patients compared to lower risk patients.22 However, studies have shown a problem of CSF 
overutilization in high-risk regimens and underutilization in low-risk regimens.21,114 No 
high-risk regimens were identified in the dataset used for this study, which could be due to 
the patient population being metastatic. Also, in the literature as well as guidelines, CSF 
administration is not considered as suitable for low and intermediate risk regimens, but 
CSF use was observed in both low and intermediate risk patients in this study. However, 
due to lack of data, it was not possible to assess if patients in this study received CSF 
reactively.. Given that the guidelines support alternatives to CSF administration such as 
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dose reduction and dose delays, and there is no evidence of the benefit of CSF over dose 
reduction in metastatic tumors, interventions to reduce CSF use in this population are 
justified.  
5.2.2 Dose Reduction, Compliance to Guidelines and Impact of Guidelines on CSF 
Use 
 Cancer consortiums such as ASCO, NCCN and EORTC all recommend using CSF 
for patients at high risk. No high-risk regimens were identified in the dataset, so compliance 
for this study meant not receiving CSF. However, ASCO supports use of viable alternatives 
like dose reduction. In this study, the percentage of patients that received dose reduction in 
the pre-period was 59 percent, which overall was moderate, even though the dose reduction 
data was incomplete. A study that estimated the incidence of dose reductions across various 
types of cancer reported a range of 22.3 – 93.1 percent,133 although their definition of dose 
reduction was a 15 percent reduction in chemotherapy dose compared to the standard dose, 
while in this study dose reduction was operationalized as a 10 percent reduction in 
chemotherapy dose compared to standard dose. Unfortunately, data were unavailable to 
assess the prevalence of dose reduction during the post-period and if the program initiative 
made any impact on physicians’ decisions to dose reduce.  
 Results of this study reveal that educational and regulatory interventions in 
healthcare settings could have an impact on prescribing behaviors. The pre vs post analysis 
showed a substantial reduction in CSF use in the post-period compared to the pre-period. 
The number of patients using CSF as well as the frequency of CSF administrations were 
both lower in the post-period compared to the pre-period. Also, the proportion of patients 
 136 
that were deemed compliant in the post-period was significantly higher than that of the pre-
period. These findings are similar to a study by Trotta et al. where a pharmaceutical policy 
educational intervention based on regional guidance on CSF prescription led to a 
significant decrease in prescription of pegfilgrastim.11 Another study found that a peer 
consultation and prescription review intervention reduced inappropriate use of 
pegfilgrastim, without compromising health outcomes.134  
5.2.3 Predictors of Dose Reduction 
 Though guidelines and evidence emphasize the necessity of a full dose intensity for 
optimal health outcomes, dose reductions and delays are often necessary due to 
complications like FN. A few studies have assessed factors that influence dose reduction, 
primary dose reduction, dose delays and/or reduced relative dose intensity. In the literature, 
primary dose reduction often refers to dose reduction at first chemotherapy cycle,135 while 
relative dose intensity (RDI) is defined as the ratio of delivered dose intensity to the 
standard or planned dose intensity.136 Though both dose delays and reduced RDI were not 
assessed in our study, the terms are related, and findings are comparable.  
 Chemotherapy dose reduction was common in this population (58.7%), when 
compared to a study of breast cancer patients that found 20 percent of dose reduction and 
31 percent of dose delays.137 The assessment in this study showed that FN risk is a 
significant predictor of dose reduction, which correlates with findings in previous 
studies.137 However, no significant association between age and dose reduction was found, 
which contrasts with other studies that have found significance with age. Particularly, 
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studies have found an association between advanced age and a reduced RDI,133,137 as well 
as between increasing age and primary dose reduction.135 This is expected because older 
patients may be unable to cope with the dose intensity of standard regimens and thus have 
their doses reduced.133 The reason for the conflicting findings between the literature and 
this study could be the missingness of the dose reduction variable.  
5.2.4 Predictors of CSF Use 
 The analyses demonstrate that FN risk, age, gender, line of therapy and duration of 
treatment are significant predictors of CSF use, with FN risk as the strongest predictor. In 
line with these findings, a recent retrospective study that assessed CSF use with Medicare 
data found that most CSF use was for high-risk regimens. The researchers also found 
greater CSF use in later cycles of therapy, while this study showed higher use in second 
line of therapy compared to first line, and lower use in third line of therapy compared to 
first line. Although evidence shows age (being >65) as a critical risk factor in developing 
FN among cancer patients undergoing myelosuppressive chemotherapy,111 justifying the 
need for CSF in older patients, this study found a negative association with age. Likewise, 
some studies have found that younger patients are more likely to receive CSF,9,12 which 
could be due to younger patients receiving more intense regimens which puts them at 
higher risk of FN compared to older patients. The negative association found with age in 
this study could be due to physicians deciding on more aggressive treatments which is more 
tolerable at a younger age. This is important, because aggressive chemotherapy in older 
and metastatic patients could have a negative effect on patient experiences, and reduce their 
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quality of life, especially in the last 30 days of life. For this population, it may be more 
beneficial to dose reduce, which still reduces the risk of FN, and allows for a better quality 
of life and healthcare experience, for both the patient and family. 
 For this study, there were no data available on some factors that have been shown 
to be predictors of CSF use, including physician factors,20 history of infections, antibiotic 
administrations and comorbidity.9,138 Comorbidities are especially important given the age 
distribution of the population in this study and the metastases state of their tumor. It is very 
likely that comorbidities would have been important in the physicians’ assessment of risk 
and need for CSF medications.  
 In the post-period analysis, there was no significant predictor of CSF use and the 
variations that were significant in the pre-period analysis disappeared. This shows that 
physicians’ prescribing practices changed due to the program initiative.  
5.2.5 Predictors of All-Cause Mortality 
 The overall mortality in the population was high at 54.2 percent, when compared 
to a study that found 9.5 percent though that was for in-patient mortality. In addition to 
age, gender, line of therapy and duration of treatment were associated with mortality. The 
use of CSF in this population did not influence mortality. This correlates with the findings 
of a meta-analysis of RCTs by Clark et al. that found no influence of CSF use on overall 
mortality among cancer patients, but did find marginal significance for infection related 
mortality.139 Conversely, some studies have found that CSF administration led to a 
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significant reduction in overall mortality,140 infection related mortality and early 
mortality.15  
 Other studies have found factors such as comorbidities, infections and infection-
related complications to be associated with mortality.69,141 
5.2.6 Comparative Effectiveness of CSF Use vs Dose Reduction on All-Cause   
 Mortality 
 The effectiveness of CSF in reducing FN events and leading to better health 
outcomes when used for prophylaxis is well documented. Dose reduction has also been 
shown to play a role in reducing myelosuppression. In comparing dose reduction to CSF 
use and their effect on mortality, this study found no difference in odds of death between 
CSF users and patients who received dose reduction. This is important because if there is 
no difference in the clinical outcomes of both risk reduction strategies, then the cost-
effective approach, which is dose reduction, should be used for this population. Studies 
that compare CSF use to dose reduction in terms of health outcomes are lacking. This 
finding fills a gap in the literature and yet address a key issue that is important to payers 
and providers and essential to patient care. 
5.3 IMPLICATIONS  
 There are some economic and clinical implications of this study. For the oncology 
network whose data were used for this study, expenditure on CSFs have been a concern for 
years, especially in the pre-period. In 2015, pegfilgrastim was the highest individual drug 
in billed claims in the network, even though evidence of its benefit for metastatic solid 
tumors is lacking. From the results of this study, one can estimate significant savings to 
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payers and buyers. If the significant reduction in CSF use observed in the post-period is 
sustained over time, and prescribers incorporate the new evidence and adopt the dose 
reduction approach for this population, increase in savings could be recorded, while 
maintaining optimal health outcomes. 
5.4 FUTURE DIRECTIONS 
 There are opportunities for future research identified in this study. To better assess 
the impact of program initiatives on prescription patterns, a time series analysis could be 
employed to evaluate the longitudinal effects of the initiative and study the trends at 
different time points. Due to data constraints, there are several variables of interest (e.g., 
comorbidities, infections) not explored in this study, which future researchers may include 
and assess. Also, although we found no difference in mortality between patients who 
received CSF and those who received dose reduction, mortality alone does not capture the 
totality of clinical outcomes. Other health outcomes indices that may be of interest to future 
researchers include number of hospitalizations, length of stay, urgent visits, ED visits, 
patient satisfaction and health-related quality of life. Future studies are also needed to 
assess and compare the occurrence of FN and infections in the two groups (CSF users vs 
patients who received dose reduction).    
5.5 STUDY LIMITATIONS 
There are several shortcomings in this study which have been categorized into data and 
methodological limitations.  
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Data Limitations 
 Firstly, the data used in this study were obtained from the electronic health records 
of patients, so there is the possibility of coding inaccuracies especially with data like CSF 
use and chemotherapy dates. Secondly, the dose reduction variable was obtained via review 
and calculations of dosing data on patient charts, which is unstructured and may also have 
problems of inaccuracy. Thirdly, the data do not detail other disease-specific or patient-
specific factors or treatment intent that were probably considered by the physician prior to 
regimen choice. For instance, studies have shown that the presence of chronic 
comorbidities increases a patient’s risk of FN.138 So it is likely that physicians considered 
comorbidities in their risk assessment prior to CSF administration, though the data are not 
available. Moreover, CSF can be used both prophylactically or therapeutically, and 
prophylactic use can be either primary or secondary. However, the intent of use was not 
captured in the data, making it difficult to distinguish if CSF use was prophylactic or 
therapeutic. Finally, the occurrence of febrile neutropenia or other neutropenic events  was 
also not contained in the data.  
Methodological Limitations 
 Commonly, it is recommended that the risk of FN be evaluated by the physician 
before the first chemotherapy cycle. This risk assessment is often based on patient-, 
disease- and treatment-related factors, in addition to chemotherapy regimen. Then, the 
patient is assigned either to a high , intermediate or low risk group. However, there is no 
general consensus on risk assessment. While both ASCO and NCCN have their criteria to 
aid in the assessment, physicians may also exercise clinical judgment for individual 
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cases.142 FN risk in this study was based on chemotherapy regimen found in the data, which 
could be a misrepresentation.  Also, a few of the chemotherapy regimens found in the data 
are not included in the examples provided by NCCN and thus were classified as missing 
values. 
 In this study, some patients received both CSF and dose reduction, but it was not 
indicated which was given before the other. Use of CSF may have been due to specific 
instances of febrile neutropenia and at the physician’s discretion, but data were not 
available for occurrence of febrile neutropenia. 
 Furthermore, the post-period in this study had a short follow-up (6 months) and it 
may be too early to tell if the noted change in prescription patterns would remain stable 
over time.  
5.6 CONCLUSIONS 
 This study investigated and compared the use of CSF and chemotherapy dose 
reduction among metastatic colorectal cancer patients and factors that influence their use. 
The results provide estimates of CSF use and patterns of use among the patients, within 
two time periods. Results demonstrate  that CSF use was significantly lower in the post-
period, compared to the pre-period. This means that a program initiative that involves 
education of oncologists, as well as monitoring of CSF prescriptions could significantly 
alter and positively impact prescription patterns. This approach should be adopted by 
oncology practices as this could reduce CSF overutilization and improve cost savings.  
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 The multivariate models presented also show the risk factors that predict CSF use 
as well as dose reduction. FN risk was the most significant predictor of both CSF use and 
dose reduction. This means that a patient’s risk of FN had the greatest influence on a 
physician’s decision to administer CSF or to dose reduce. The study also investigated risk 
factors that predict mortality in this population, which revealed age and line of therapy as 
the most significant predictors. While this is vital information, survival analysis involving 
Kaplan-Meier methods and cox proportional models could be used to better understand the 
relationships between these predictors and risk of death. 
 Furthermore, the results showed no difference in odds of death between CSF users 
and patients who received dose reduction. This indicates no benefit of CSF use over dose 
reduction in terms of mortality outcome. This is an important finding, given that it is more 
cost effective to dose reduce than to administer CSF. Also, this is a time where the approach 
of health delivery is aimed towards reducing costs while improving quality of care, 
employing services that are patient centered and beneficial. Therefore, this evidence, if 
incorporated into clinical practice,  could help decrease the inappropriate use of CSFs and 
may result in enhanced clinical practice and cost savings, without negatively impacting 
health outcomes. However, use of dose reduction alone in this population should be 
monitored over time to assess its impact on other health outcomes indices, and this should 
be the focus of future studies.  
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Appendix A: Histograms and QQ plots of Continuous Variables 
Figure A1: Distribution of Continuous Variable Age 
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Figure A2: Distribution of Continuous Variable Age showing Normal & Kernel 
Lines 
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Figure A3: Q-Q Plot of Continuous Variable Age 
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Figure A4: Distribution of Continuous Variable CSF Administration 
 
 
Figure A5: Distribution of Continuous Variable CSF Administration showing 
Normal & Kernel Lines 
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Figure A6: Q-Q Plot of Continuous Variable CSF Administration 
 
 
 
Figure A7: Distribution of Continuous Variable Duration of Treatment 
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Figure A8: Distribution of Continuous Variable Duration of Treatment showing 
Normal & Kernel Lines 
 
 
Figure A9: Q-Q Plot of Continuous Variable Duration of Treatment 
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Appendix B: Multicollinearity Assumption Tests 
 
Figure B1: Spearman correlation for Logistic Regression Model of CSF Use and 
Covariates in the Pre-Period 
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Spearman Correlation Coefficients  
Prob > |r| under H0: Rho=0  
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Figure B2: VIF and Tolerance for Logistic Regression Model of CSF Use and 
Covariates in the Pre-Period 
 
Parameter Estimates 
Variable DF Parameter 
Estimate 
Standard 
Error 
t Value Pr > |t| Tolerance Variance 
Inflation 
Intercept 1 0.13501 0.02664 5.07 <.0001 . 0 
FNrisk 1 0.04429 0.01483 2.99 0.0029 0.77949 1.28289 
agecat 1 -0.02490 0.00688 -3.62 0.0003 0.98705 1.01312 
sex 1 0.03430 0.01332 2.58 0.0101 0.98234 1.01798 
duracat 1 0.02038 0.01328 1.53 0.1250 0.98002 1.02039 
diagnosis 1 -0.00794 0.01248 -0.64 0.5249 0.79940 1.25094 
LOT 1 -0.01280 0.01016 -1.26 0.2079 0.70397 1.42051 
dxcat 1 -0.01611 0.01489 -1.08 0.2794 0.97300 1.02775 
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Figure B3: Spearman correlation for Logistic Regression Model of CSF Use and 
Covariates in the Post-Period 
Spearman Correlation Coefficients  
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Figure B4: VIF and Tolerance for Logistic Regression Model of CSF Use and 
Covariates in the Post-Period 
 
Parameter Estimates 
Variable DF Parameter 
Estimate 
Standard 
Error 
t Value Pr > |t| Tolerance Variance 
Inflation 
Intercept 1 0.06982 0.05266 1.33 0.1853 . 0 
FNrisk 1 0.02584 0.01635 1.58 0.1144 0.84792 1.17936 
agecat 1 -0.01477 0.00831 -1.78 0.0757 0.96898 1.03201 
sex 1 0.01740 0.01538 1.13 0.2583 0.99103 1.00905 
duracat 1 0.01122 0.03364 0.33 0.7388 0.99152 1.00855 
diagnosis 1 -0.01718 0.02496 -0.69 0.4915 0.93334 1.07142 
LOT 1 -0.00274 0.01256 -0.22 0.8276 0.81494 1.22708 
dxcat 1 0.01109 0.01764 0.63 0.5297 0.97736 1.02317 
 
 
 
 
 
Figure B5: Spearman Correlation for Logistic Regression Model of Dose Reduction 
and Covariates 
 
Spearman Correlation Coefficients  
Prob > |r| under H0: Rho=0  
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Spearman Correlation Coefficients  
Prob > |r| under H0: Rho=0  
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Figure B6: VIF and Tolerance Logistic Regression Model of dose reduction and 
Covariates 
Parameter Estimates 
Variable DF Parameter 
Estimate 
Standard 
Error 
t Value Pr > |t| Tolerance Variance 
Inflation 
Intercept 1 0.45738 0.09172 4.99 <.0001 . 0 
FNrisk 1 0.14869 0.04859 3.06 0.0023 0.79203 1.26259 
agecat 1 -0.00497 0.02701 -0.18 0.8541 0.97415 1.02653 
sex 1 0.03297 0.04444 0.74 0.4585 0.98536 1.01485 
duracat 1 0.17137 0.03897 4.40 <.0001 0.98743 1.01273 
diagnosis 1 0.00016828 0.03976 0.00 0.9966 0.79728 1.25426 
LOT 1 -0.01289 0.03667 -0.35 0.7253 0.73699 1.35687 
dxcat 1 0.09624 0.05247 1.83 0.0673 0.97451 1.02616 
 
 
Figure B7: Spearman correlation for Logistic Regression Model of Mortality and 
Covariates 
Spearman Correlation Coefficients  
Prob > |r| under H0: Rho=0  
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Spearman Correlation Coefficients  
Prob > |r| under H0: Rho=0  
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Spearman Correlation Coefficients  
Prob > |r| under H0: Rho=0  
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Figure B8: VIF and Tolerance Logistic Regression Model of Mortality and 
Covariates 
 
Parameter Estimates 
Variable DF Parameter 
Estimate 
Standard 
Error 
t Value Pr > |t| Tolerance Variance 
Inflation 
Intercept 1 0.67920 0.08255 8.23 <.0001 . 0 
csfuse 1 0.05428 0.12309 0.44 0.6595 0.91207 1.09641 
dosered 1 -0.05686 0.04154 -1.37 0.1717 0.87832 1.13854 
FNrisk 1 -0.12458 0.04269 -2.92 0.0037 0.76591 1.30563 
agecat 1 0.06128 0.02335 2.62 0.0090 0.97268 1.02809 
sex 1 -0.10985 0.03841 -2.86 0.0044 0.98413 1.01612 
duracat 1 -0.12127 0.03438 -3.53 0.0005 0.94685 1.05613 
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Parameter Estimates 
Variable DF Parameter 
Estimate 
Standard 
Error 
t Value Pr > |t| Tolerance Variance 
Inflation 
diagnosis 1 0.10154 0.03436 2.96 0.0033 0.79711 1.25453 
LOT 1 0.07961 0.03169 2.51 0.0124 0.73640 1.35796 
dxcat 1 -0.04112 0.04598 -0.89 0.3716 0.94703 1.05593 
 
 
 
Figure B9: Spearman correlation for Logistic Regression Model of Mortality and 
Compare 
Spearman Correlation Coefficients  
Prob > |r| under H0: Rho=0  
Number of Observations 
  compare FNrisk agecat sex duracat diagnosis LOT 
compare 1.00000 
  
598 
 
0.00506 
0.9029 
584 
 
-0.48878 
<.0001 
598 
 
0.06098 
0.1364 
598 
 
-0.03359 
0.4122 
598 
 
0.02421 
0.5546 
598 
 
0.10791 
0.0083 
598 
 
FNrisk 0.00506 
0.9029 
584 
 
1.00000 
  
2477 
 
-0.02208 
0.2720 
2477 
 
0.02771 
0.1679 
2477 
 
0.00614 
0.7601 
2477 
 
0.32993 
<.0001 
2477 
 
-0.51091 
<.0001 
2477 
 
agecat -0.48878 
<.0001 
598 
 
-0.02208 
0.2720 
2477 
 
1.00000 
  
2541 
 
0.02879 
0.1468 
2541 
 
-0.01811 
0.3615 
2541 
 
-0.01448 
0.4656 
2541 
 
-0.03297 
0.0966 
2541 
 
sex 0.06098 
0.1364 
598 
 
0.02771 
0.1679 
2477 
 
0.02879 
0.1468 
2541 
 
1.00000 
  
2541 
 
0.03335 
0.0928 
2541 
 
0.03572 
0.0718 
2541 
 
-0.01848 
0.3518 
2541 
 
duracat -0.03359 
0.4122 
0.00614 
0.7601 
-0.01811 
0.3615 
0.03335 
0.0928 
1.00000 
  
-0.04510 
0.0230 
-0.09047 
<.0001 
 160 
Spearman Correlation Coefficients  
Prob > |r| under H0: Rho=0  
Number of Observations 
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Figure B10: VIF and Tolerance for Logistic Regression Model of Mortality and 
Compare 
Parameter Estimates 
Variable DF Parameter 
Estimate 
Standard 
Error 
t Value Pr > |t| Tolerance Variance 
Inflation 
Intercept 1 0.54642 0.07783 7.02 <.0001 . 0 
compare 1 -0.04660 0.04226 -1.10 0.2706 0.76034 1.31520 
FNrisk 1 -0.05016 0.04164 -1.20 0.2288 0.78758 1.26971 
agecat 1 0.11512 0.02218 5.19 <.0001 0.76899 1.30041 
sex 1 -0.16339 0.03746 -4.36 <.0001 0.97963 1.02079 
duracat 1 -0.07973 0.03203 -2.49 0.0131 0.96380 1.03756 
diagnosis 1 0.04209 0.03476 1.21 0.2264 0.82979 1.20512 
LOT 1 0.11416 0.03473 3.29 0.0011 0.72544 1.37846 
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ACRONYMS 
ABIM American Board of Internal Medicine 
ACS American Cancer Society 
AJCC American Joint Committee on Cancer 
ANC Absolute Neutrophil Count 
API Asian & Pacific Islanders 
ASCO American Society of Clinical Oncology 
CanCORS Cancer Care Outcomes Research and Surveillance 
CBC Complete Blood Count  
CT Computed Topography 
CSF Colony Stimulating Factors 
DCBE Double-Contrast Barium Enema 
EGFR Epidermal Growth Factor Receptor 
EORTC European Organization for Research and Treatment of Cancer 
ESMO European Society of Medical Oncology 
FIT Fecal Immunochemical Test 
FN Febrile Neutropenia 
G-CSF Granulocyte Colony Stimulating Factors 
GM-CSF Granulocyte Macrophage Colony Stimulating Factors 
gFOBT Guaiac-based Fecal Occult Blood Tests 
iFOBT Immunochemical Fecal Occult Blood Test 
IL-3 Interleukin 3 
IRB Institutional Review Board 
LOT Line of Therapy 
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MASCC Multinational Association of Supportive Care in Cancer 
M-CSF Macrophage Colony Stimulating Factors 
MEPS Medical Expenditure Panel Survey 
NCCN National Comprehensive Cancer Network 
NHB Non-Hispanic Blacks 
NHW Non-Hispanic Whites 
OCM Oncology Care Model 
RCT Randomized Controlled Trials 
RDI Reduced Dose Intensity  
SEER Surveillance, Epidemiology and End Results 
TNM Tumor, Lymph Nodes, Metastasis 
USPSTF United States Preventive Services Task Force 
VEGF Vascular Endothelial Growth Factor Inhibitor 
VIF Variance Inflation Factor 
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